

Published in final edited form as:

Nat Genet. 2020 May 01; 52(5): 482–493. doi:10.1038/s41588-020-0610-9.

Genetic Identification of Cell Types Underlying Brain Complex Traits Yields Insights Into the Etiology of Parkinson's Disease

Julien Bryois^{#1}, Nathan G. Skene^{#2,3,4,5}, Thomas Folkmann Hansen^{6,7,8}, Lisette J. A. Kogelman⁶, Hunna J. Watson^{9,10,11}, Zijing Liu^{4,5}, Eating Disorders Working Group of the Psychiatric Genomics Consortium
 Roger Adan^{18,19,20}, Lars Alfredsson²¹, Tetsuya Ando²², Ole Andreassen²³, Jessica Baker⁹, Andrew Bergen^{24,25}, Wade Berrettini²⁶, Andreas Birgegård^{27,28}, Joseph Boden²⁹, Ilka Boehm³⁰, Claudette Boni³¹, Vesna Boraska Perica^{32,33}, Harry Brandt³⁴, Gerome Breen^{14,15}, Julien Bryois¹, Katharina Buehren³⁵, Cynthia Bulik^{1,9,16}, Roland Burghardt³⁶, Matteo Cassina³⁷, Sven Cichon³⁸, Maurizio Clementi³⁷, Jonathan Coleman^{14,15}, Roger Cone³⁹, Philippe Courtet⁴⁰, Steven Crawford³⁴, Scott Crow⁴¹, James Crowley^{17,27}, Unna Danner¹⁹, Oliver Davis^{42,43}, Martina de Zwaan⁴⁴, George Dedoussis⁴⁵, Daniela Degortes⁴⁶, Janiece DeSocio⁴⁷, Danielle Dick⁴⁸, Dimitris Dikeos⁴⁹, Christian Dina^{50,51}, Monika Dmitrzak-Weglarz⁵², Elisa Docampo Martinez^{53,54,55}, Laramie Duncan⁵⁶, Karin Egberts⁵⁷, Stefan Ehrlich³⁰, Geòrgia Escaramis^{53,54,55}, Tõnu Esko^{58,59}, Xavier Estivill^{53,54,55,60}, Anne Farmer¹⁴, Angela Favaro⁴⁶, Fernando Fernández-Aranda^{61,62}, Manfred Fichter^{63,64}, Krista Fischer⁵⁸, Manuel Föcker⁶⁵, Lenka Foretova⁶⁶, Andreas Forstner^{38,67,68,69,70}, Monica Forzan³⁷, Christopher Franklin³², Steven Gallinger⁷¹, Héléna Gaspar^{14,15}, Ina Giegling⁷², Johanna Giuranna⁶⁵, Paola Giusti-Rodríguez¹⁷, Fragiskos Gonidakis⁷³, Scott Gordon⁷⁴, Philip Gorwood^{31,75}, Monica Gratacos Mayora^{53,54,55}, Jakob Grove^{76,77,78,79}, Sébastien Guillaume⁴⁰, Yiran Guo⁸⁰, Hakon Hakonarson^{80,81}, Katherine Halmi⁸², Ken Hanscombe⁸³, Konstantinos Hatzikotoulas³², Joanna Hauser⁸⁴, Johannes Hebebrand⁶⁵, Sietske Helder^{14,85}, Anjali Henders⁸⁶, Stefan Herms^{38,70}, Beate Herpertz-Dahlmann³⁵, Wolfgang Herzog⁸⁷, Anke Hinney⁶⁵, L. John Horwood²⁹, Christopher Hübel^{14,1}, Laura Huckins^{32,88}, James Hudson⁸⁹, Hartmut Imgart⁹⁰, Hidetoshi Inoko⁹¹, Vladimir Janout⁹², Susana Jiménez-Murcia^{61,62}, Craig Johnson⁹³, Jennifer Jordan^{94,95}, Antonio Julià⁹⁶, Anders Juréus¹, Gursharan Kalsi¹⁴, Deborah Kaminská⁹⁷, Allan Kaplan⁹⁸, Jaakko Kaprio^{99,100}, Leila Karhunen¹⁰¹, Andreas Karwautz¹⁰², Martien Kas^{18,103}, Walter Kaye¹⁰⁴, James Kennedy⁹⁸,

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

*Correspond with Drs Sullivan (patrick.sullivan@ki.se) and Hjerling-Leffler (jens.hjerling-leffler@ki.se).

Author contributions

J.B., N.G.S., J.H.-L. and P.F.S. designed the study, wrote and reviewed the manuscript; J.B performed the analyses pertaining to Fig. 1–4, Extended Data Figure 1–10, Supplementary Fig. 1–5,7–20, Supplementary Table 1–9,12–17; N.G.S performed the analyses pertaining to Fig. 5, Supplementary Fig. 6 and Supplementary Table 10,11; T.F.H, L.J.A.K. and the I.H.G.C provided the migraine GWAS summary statistics; H.J.W., the E.D.W.G.P.G.C, G.B. and C.M.B performed the anorexia GWAS; Z.L. contributed to the revision of the manuscript, The 23andMe R.T. provided GWAS summary statistics for Parkinson's disease in the 23andMe cohort. L.B. contributed to the post-mortem differential expression analysis (Fig. 5); E.A. and K.H. provided expert knowledge on Parkinson's disease and reviewed the manuscript.

Conflicts of interest

P.F.S. reports the following potentially competing financial interests. Current: Lundbeck (advisory committee, grant recipient). Past three years: Pfizer (scientific advisory board), Element Genomics (consultation fee), and Roche (speaker reimbursement). C.M. Bulik reports: Shire (grant recipient, Scientific Advisory Board member); Pearson and Walker (author, royalty recipient).

Martin Kennedy¹⁰⁵, Anna Keski-Rahkonen⁹⁹, Kirsty Kiezebrink¹⁰⁶, Youl-Ri Kim¹⁰⁷, Katherine Kirk⁷⁴, Lars Klareskog¹⁰⁸, Kelly Klump¹⁰⁹, Gun Peggy Knudsen¹¹⁰, Maria La Via⁹, Mikael Landén^{1,20}, Janne Larsen^{77,111,112}, Stephanie Le Hellard^{113,114,115}, Virpi Leppä¹, Robert Levitan¹¹⁶, Dong Li⁸⁰, Paul Lichtenstein¹, Lisa Lilienfeld¹¹⁷, Bochao Danae Lin¹⁸, Jolanta Lissowska¹¹⁸, Jurjen Luykx¹⁸, Pierre Magistretti^{119,120}, Mario Maj¹²¹, Katrin Mannik^{58,122}, Sara Marsal⁹⁶, Christian Marshall¹²³, Nicholas Martin⁷⁴, Manuel Mattheisen^{76,27,28,124}, Morten Mattingsdal²³, Sara McDevitt^{125,126}, Peter McGuffin¹⁴, Sarah Medland⁷⁴, Andres Metspalu^{58,127}, Ingrid Meulenbelt¹²⁸, Nadia Micali^{129,130}, James Mitchell¹³¹, Karen Mitchell¹³², Palmiero Monteleone¹³³, Alessio Maria Monteleone¹²¹, Grant Montgomery^{74,86,134}, Preben Bo Mortensen^{77,111,112}, Melissa Munn-Chernoff⁹, Benedetta Nacmias¹³⁵, Marie Navratilova⁶⁶, Claes Noring^{27,28}, Ioanna Ntalla⁴⁵, Catherine Olsen⁷⁴, Roel Ophoff^{18,136}, Julie O'Toole¹³⁷, Leonid Padyukov¹⁰⁸, Aarno Palotie^{59,100,138}, Jacques Pantel³¹, Hana Papezova⁹⁷, Richard Parker⁷⁴, John Pearson¹³⁹, Nancy Pedersen¹, Liselotte Petersen^{77,111,112}, Dalila Pinto⁸⁸, Kirstin Purves¹⁴, Raquel Rabionet^{140,141,142}, Anu Raevuori⁹⁹, Nicolas Ramoz³¹, Ted Reichborn-Kjennerud^{110,143}, Valdo Ricca^{135,144}, Samuli Ripatti¹⁴⁵, Stephan Ripke^{146,147,148}, Franziska Ritschel^{30,149}, Marion Roberts¹⁴, Alessandro Rotondo¹⁵⁰, Dan Rujescu^{63,72}, Filip Rybakowski¹⁵¹, Paolo Santonastaso¹⁵², André Scherag¹⁵³, Stephen Scherer¹⁵⁴, Ulrike Schmidt¹⁴, Nicholas Schork¹⁵⁵, Alexandra Schosser¹⁵⁶, Jochen Seitz³⁵, Lenka Slachtova¹⁵⁷, P. Eline Slagboom¹²⁸, Margarita Slof-Op 't Landt^{158,159}, Agnieszka Slopian¹⁶⁰, Sandro Sorbi^{135,161}, Michael Strober^{162,163}, Garret Stuber^{9,164}, Patrick Sullivan^{1,17}, Beata Witkowska¹⁶⁵, Jin Szatkiewicz¹⁷, Ioanna Tachmazidou³², Elena Tenconi⁴⁶, Laura Thornton⁹, Alfonso Tortorella^{166,167}, Federica Tozzi¹⁶⁸, Janet Treasure¹⁴, Artemis Tsitsika¹⁶⁹, Marta Tyszkiewicz-Nwafor¹⁵¹, Konstantinos Tziouvas¹⁷⁰, Annemarie van Elburg^{19,171}, Eric van Furth^{158,159}, Tracey Wade¹⁷², Gudrun Wagner¹⁰², Esther Walton³⁰, Hunna Watson^{9,10,11}, Thomas Werge¹⁷³, David Whiteman⁷⁴, Elisabeth Widen¹⁰⁰, D. Blake Woodside^{174,175}, Shuyang Yao¹, Zeynep Yilmaz^{9,17}, Eleftheria Zeggini^{32,176}, Stephanie Zerwas⁹, Stephan Zipfel¹⁷⁷

¹⁸Brain Center Rudolf Magnus, Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands

¹⁹Center for Eating Disorders Rintveld, Altrecht Mental Health Institute, Zeist, The Netherlands

²⁰Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

²¹Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

²²Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan

²³NORMENT KG Jebsen Centre, Division of Mental Health and Addiction, University of Oslo, Oslo University Hospital, Oslo, Norway

²⁴BioRealm, LLC, Walnut, California, US

²⁵Oregon Research Institute, Eugene, Oregon, US

²⁶Department of Psychiatry, Center for Neurobiology and Behavior, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, US

- ²⁷Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden**
- ²⁸Center for Psychiatry Research, Stockholm Health Care Services, Stockholm City Council, Stockholm, Sweden**
- ²⁹Christchurch Health and Development Study, University of Otago, Christchurch, New Zealand**
- ³⁰Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany**
- ³¹INSERM U894, Centre of Psychiatry and Neuroscience, Paris, France**
- ³²Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK**
- ³³Department of Medical Biology, School of Medicine, University of Split, Split, Croatia**
- ³⁴The Center for Eating Disorders at Sheppard Pratt, Baltimore, Maryland, US**
- ³⁵Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany**
- ³⁶Klinikum Frankfurt/Oder, Frankfurt, Germany**
- ³⁷Clinical Genetics Unit, Department of Woman and Child Health, University of Padova, Padova, Italy**
- ³⁸Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland**
- ³⁹Life Sciences Institute and Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, US**
- ⁴⁰Department of Emergency Psychiatry and Post-Acute Care, CHRU Montpellier, University of Montpellier, Montpellier, France**
- ⁴¹Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, US**
- ⁴²MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK**
- ⁴³School of Social and Community Medicine, University of Bristol, Bristol, UK**
- ⁴⁴Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany**
- ⁴⁵Department of Nutrition and Dietetics, Harokopio University, Athens, Greece**
- ⁴⁶Department of Neurosciences, University of Padova, Padova, Italy**
- ⁴⁷College of Nursing, Seattle University, Seattle, Washington, US**
- ⁴⁸Department of Psychology, Virginia Commonwealth University, Richmond, Virginia, US**
- ⁴⁹Department of Psychiatry, Athens University Medical School, Athens University, Athens, Greece**
- ⁵⁰L'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France**
- ⁵¹L'institut du thorax, CHU Nantes, Nantes, France**

- ⁵²Department of Psychiatric Genetics, Poznan University of Medical Sciences, Poznan, Poland**
- ⁵³Barcelona Institute of Science and Technology, Barcelona, Spain**
- ⁵⁴Universitat Pompeu Fabra, Barcelona, Spain**
- ⁵⁵Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain**
- ⁵⁶Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, US**
- ⁵⁷Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Centre for Mental Health, Würzburg, Germany**
- ⁵⁸Estonian Genome Center, University of Tartu, Tartu, Estonia**
- ⁵⁹Program in Medical and Population Genetics, Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, US**
- ⁶⁰Genomics and Disease, Bioinformatics and Genomics Programme, Centre for Genomic Regulation, Barcelona, Spain**
- ⁶¹Department of Psychiatry, University Hospital of Bellvitge –IDIBELL and CIBERObn, Barcelona, Spain**
- ⁶²Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain**
- ⁶³Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University (LMU), Munich, Germany**
- ⁶⁴Schön Klinik Roseneck affiliated with the Medical Faculty of the University of Munich (LMU), Munich, Germany**
- ⁶⁵Department of Child and Adolescent Psychiatry, University Hospital Essen, University of Duisburg-Essen, Essen, Germany**
- ⁶⁶Department of Cancer, Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic**
- ⁶⁷Institute of Human Genetics, University of Bonn School of Medicine & University Hospital Bonn, Bonn, Germany**
- ⁶⁸Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany**
- ⁶⁹Department of Psychiatry (UPK), University of Basel, Basel, Switzerland**
- ⁷⁰Department of Biomedicine, University of Basel, Basel, Switzerland**
- ⁷¹Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, Canada**
- ⁷²Department of Psychiatry, Psychotherapy and Psychosomatics, Martin Luther University of Halle-Wittenberg, Halle, Germany**

- ⁷³1st Psychiatric Department, National and Kapodistrian University of Athens, Medical School, Eginition Hospital, Athens, Greece**
- ⁷⁴QIMR Berghofer Medical Research Institute, Brisbane, Australia**
- ⁷⁵CMME (Groupe Hospitalier Sainte-Anne), Paris Descartes University, Paris, France**
- ⁷⁶Department of Biomedicine, Aarhus University, Aarhus, Denmark**
- ⁷⁷The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark**
- ⁷⁸Centre for Integrative Sequencing, iSEQ, Aarhus University, Aarhus, Denmark**
- ⁷⁹Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark**
- ⁸⁰Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, US**
- ⁸¹Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, US**
- ⁸²Department of Psychiatry, Weill Cornell Medical College, New York, New York, US**
- ⁸³Department of Medical and Molecular Genetics, King's College London, Guy's Hospital, London, UK**
- ⁸⁴Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland**
- ⁸⁵Zorg op Orde, Leidschendam, The Netherlands**
- ⁸⁶Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia**
- ⁸⁷Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany**
- ⁸⁸Department of Psychiatry, and Genetics and Genomics Sciences, Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, New York, US**
- ⁸⁹Biological Psychiatry Laboratory, McLean Hospital/Harvard Medical School, Boston, Massachusetts, US**
- ⁹⁰Eating Disorders Unit, Parklandklinik, Bad Wildungen, Germany**
- ⁹¹Department of Molecular Life Science, Division of Basic Medical Science and Molecular Medicine, School of Medicine, Tokai University, Isehara, Japan**
- ⁹²Faculty of Health Sciences, Palacky University, Olomouc, Czech Republic**
- ⁹³Eating Recovery Center, Denver, Colorado, US**
- ⁹⁴Department of Psychological Medicine, University of Otago, Christchurch, New Zealand**
- ⁹⁵Canterbury District Health Board, Christchurch, New Zealand**
- ⁹⁶Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain**
- ⁹⁷Department of Psychiatry, First Faculty of Medicine, Charles University, Prague, Czech Republic**

- ⁹⁸Center for Addiction and Mental Health, Department of Psychiatry, Institute of Medical Science, University of Toronto, Toronto, Canada**
- ⁹⁹Department of Public Health, University of Helsinki, Helsinki, Finland**
- ¹⁰⁰Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland**
- ¹⁰¹Institute of Public Health and Clinical Nutrition, Department of Clinical Nutrition, University of Eastern Finland, Kuopio, Finland**
- ¹⁰²Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria**
- ¹⁰³Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands**
- ¹⁰⁴Department of Psychiatry, University of California San Diego, San Diego, California, US**
- ¹⁰⁵Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand**
- ¹⁰⁶Health Services Research Unit, University of Aberdeen, Aberdeen, UK**
- ¹⁰⁷Department of Psychiatry, Seoul Paik Hospital, Inje University, Seoul, Korea**
- ¹⁰⁸Rheumatology Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden**
- ¹⁰⁹Department of Psychology, Michigan State University, East Lansing, Michigan, US**
- ¹¹⁰Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway**
- ¹¹¹National Centre for Register-Based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark**
- ¹¹²Centre for Integrated Register-based Research (CIRRAU), Aarhus University, Aarhus, Denmark**
- ¹¹³Department of Clinical Science, K.G. Jebsen Centre for Psychosis Research, Norwegian Centre for Mental Disorders Research (NORMENT), University of Bergen, Bergen, Norway**
- ¹¹⁴Dr. Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway**
- ¹¹⁵Department of Clinical Medicine, Laboratory Building, Haukeland University Hospital, Bergen, Norway**
- ¹¹⁶Institute of Medical Science, University of Toronto, Toronto, Canada**
- ¹¹⁷American School of Professional Psychology, Argosy University, Northern Virginia, Arlington, Virginia, US**
- ¹¹⁸Department of Cancer Epidemiology and Prevention, M Skłodowska-Curie Cancer Center - Oncology Center, Warsaw, Poland**

- ¹¹⁹BESE Division, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia**
- ¹²⁰Department of Psychiatry, University of Lausanne-University Hospital of Lausanne (UNIL-CHUV), Lausanne, Switzerland**
- ¹²¹Department of Psychiatry, University of Campania "Luigi Vanvitelli", Naples, Italy**
- ¹²²Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland**
- ¹²³Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada**
- ¹²⁴Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany**
- ¹²⁵Department of Psychiatry, University College Cork, Cork, Ireland**
- ¹²⁶Eist Linn Adolescent Unit, Bessborough, Health Service Executive South, Cork, Ireland**
- ¹²⁷Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia**
- ¹²⁸Molecular Epidemiology Section (Department of Medical Statistics), Leiden University Medical Centre, Leiden, The Netherlands**
- ¹²⁹Department of Psychiatry, Faculty of Medicine, University of Geneva, Geneva, Switzerland**
- ¹³⁰Division of Child and Adolescent Psychiatry, Geneva University Hospital, Geneva, Switzerland**
- ¹³¹Department of Psychiatry and Behavioral Science, University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota, US**
- ¹³²National Center for PTSD, VA Boston Healthcare System, Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, US**
- ¹³³Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy**
- ¹³⁴Queensland Brain Institute, University of Queensland, Brisbane, Australia**
- ¹³⁵Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy**
- ¹³⁶Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, US**
- ¹³⁷Kartini Clinic, Portland, Oregon, US**
- ¹³⁸Center for Human Genome Research at the Massachusetts General Hospital, Boston, Massachusetts, US**
- ¹³⁹Biostatistics and Computational Biology Unit, University of Otago, Christchurch, New Zealand**

- ¹⁴⁰Saint Joan de Déu Research Institute, Saint Joan de Déu Barcelona Children's Hospital, Barcelona, Spain**
- ¹⁴¹Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain**
- ¹⁴²Department of Genetics, Microbiology and Statistics, University of Barcelona, Barcelona, Spain**
- ¹⁴³Institute of Clinical Medicine, University of Oslo, Oslo, Norway**
- ¹⁴⁴Department of Health Science, University of Florence, Florence, Italy**
- ¹⁴⁵Department of Biometry, University of Helsinki, Helsinki, Finland**
- ¹⁴⁶Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, US**
- ¹⁴⁷Stanley Center for Psychiatric Research, Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, US**
- ¹⁴⁸Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin, Berlin, Germany**
- ¹⁴⁹Eating Disorders Research and Treatment Center, Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany**
- ¹⁵⁰Department of Psychiatry, Neurobiology, Pharmacology, and Biotechnologies, University of Pisa, Pisa, Italy**
- ¹⁵¹Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland**
- ¹⁵²Department of Neurosciences, Padua Neuroscience Center, University of Padova, Padova, Italy**
- ¹⁵³Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital, Jena, Germany**
- ¹⁵⁴Department of Genetics and Genomic Biology, The Hospital for Sick Children, Toronto, Canada**
- ¹⁵⁵J. Craig Venter Institute (JCVI), La Jolla, California, US**
- ¹⁵⁶Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria**
- ¹⁵⁷Department of Pediatrics and Center of Applied Genomics, First Faculty of Medicine, Charles University, Prague, Czech Republic**
- ¹⁵⁸Center for Eating Disorders Ursula, Rivierduinen, Leiden, The Netherlands**
- ¹⁵⁹Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands**
- ¹⁶⁰Department of Child and Adolescent Psychiatry, Poznan University of Medical Sciences, Poznan, Poland**
- ¹⁶¹IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy**

¹⁶²Department of Psychiatry and Biobehavioral Science, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, US

¹⁶³David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, US

¹⁶⁴Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US

¹⁶⁵Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland

¹⁶⁶Department of Psychiatry, University of Naples SUN, Naples, Italy

¹⁶⁷Department of Psychiatry, University of Perugia, Perugia, Italy

¹⁶⁸Brain Sciences Department, Stremble Ventures, Limassol, Cyprus

¹⁶⁹Adolescent Health Unit, Second Department of Pediatrics, "P. & A. Kyriakou" Children's Hospital, University of Athens, Athens, Greece

¹⁷⁰Pediatric Intensive Care Unit, "P. & A. Kyriakou" Children's Hospital, University of Athens, Athens, Greece

¹⁷¹Faculty of Social and Behavioral Sciences, Utrecht University, Utrecht, The Netherlands

¹⁷²School of Psychology, Flinders University, Adelaide, Australia

¹⁷³Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark

¹⁷⁴Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Canada

¹⁷⁵Toronto General Hospital, Toronto, Canada

¹⁷⁶Institute of Translational Genomics, Helmholtz Zentrum München, Neuherberg, Germany

¹⁷⁷Department of Internal Medicine VI, Psychosomatic Medicine and Psychotherapy, University Medical Hospital Tuebingen, Tuebingen, Germany

, International Headache Genetics Consortium

Verner Anttila¹⁷⁸, Ville Artto¹⁷⁹, Andrea Carmine Belin¹⁸⁰, Irene de Boer¹⁸¹, Dorret I Boomsma¹⁸², Sigrid Børte¹⁸³, Daniel I Chasman¹⁸⁴, Lynn Cherkas¹⁸⁵, Anne Francke Christensen¹⁸⁶, Bru Cormand¹⁸⁷, Ester Cuenca-Leon¹⁷⁸, George Davey-Smith¹⁸⁸, Martin Dichgans¹⁸⁹, Cornelia van Duijn¹⁹⁰, Tonu Esko⁵⁸, Ann Louise Esserlind¹⁹¹, Michel Ferrari¹⁸¹, Rune R. Frants¹⁸¹, Tobias Freilinger¹⁹², Nick Furlotte¹⁹³, Padhraig Gormley¹⁷⁸, Lyn Griffiths¹⁹⁴, Eija Hamalainen¹⁹⁵, Thomas Folkmann Hansen⁶, Marjo Hiekkala¹⁹⁶, M Arfan Ikram¹⁹⁰, Andres Ingason¹⁹⁷, Marjo-Riitta Järvelin¹⁹⁸, Risto Kajanne¹⁹⁵, Mikko Kallela¹⁷⁹, Jaakko Kaprio^{99,100}, Mari Kaunisto¹⁹⁶, Lisette J.A. Kogelman⁶, Christian Kubisch¹⁹⁹, Mitja Kurki¹⁷⁸, Tobias Kurth²⁰⁰, Lenore Launer²⁰¹, Terho Lehtimäki²⁰², Davor Lesel¹⁹⁹, Lannie Ligthart¹⁸², Nadia Litterman¹⁹³, Arn van den Maagdenberg¹⁸¹, Alfons Macaya²⁰³, Rainer Malik¹⁸⁹, Massimo Mangino²⁰⁴, George McMahon²⁰⁵, Bertram Muller-Miyhok²⁰⁶, Benjamin M. Neale¹⁷⁸, Carrie Northover¹⁹³, Dale R. Nyholt¹⁹⁴, Jes Olesen²⁰⁷, Aarno Palotie^{59,100,138}, Priit Palta¹⁹⁵, Linda Pedersen¹⁸³, Nancy Pedersen¹, Danielle Posthuma¹⁸², Patricia Pozo-Rosich²⁰⁸, Alice Pressman²⁰⁹, Olli Raitakari²¹⁰, Markus

Schürks²⁰⁰, Celia Sintas¹⁸⁷, Kari Stefansson¹⁹⁷, Hreinn Stefansson¹⁹⁷, Stacy Steinberg¹⁹⁷, David Strachan²¹¹, Gisela Terwindt¹⁸¹, Marta Vila-Pueyo²⁰³, Maija Wessman¹⁹⁶, Bendik S. Winsvold¹⁸³, Huiying Zhao¹⁹⁴, John Anker Zwart¹⁸³

¹⁷⁸Broad Institute of MIT and Harvard, Cambridge, USA

¹⁷⁹Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland

¹⁸⁰Karolinska Institutet, Stockholm, Sweden

¹⁸¹Leiden University Medical Centre, Leiden, The Netherlands

¹⁸²VU University, Amsterdam, The Netherlands

¹⁸³Oslo University Hospital and University of Oslo, Oslo, Norway

¹⁸⁴Harvard Medical School, Cambridge, USA

¹⁸⁵Department of Twin Research and Genetic Epidemiology, King's College London, London, UK

¹⁸⁶Danish Headache Center, Copenhagen University Hospital, Copenhagen, Denmark

¹⁸⁷University of Barcelona, Barcelona, Spain

¹⁸⁸Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol, UK

¹⁸⁹Institute for Stroke and Dementia Research, Munich, Germany

¹⁹⁰Erasmus University Medical Centre, Rotterdam, The Netherlands

¹⁹¹Danish Headache Center, Department of Neurology, Rigshospitalet, Denmark

¹⁹²University of Tuebingen, Tuebingen, Germany

¹⁹³23&Me Inc., Mountain View, USA

¹⁹⁴Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia

¹⁹⁵Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland

¹⁹⁶Folkhälsan Institute of Genetics, Helsinki, Finland

¹⁹⁷Decode genetics Inc., Reykjavik, Iceland

¹⁹⁸University of Oulu, Biocenter Oulu, Finland

¹⁹⁹University Medical Center Hamburg-Eppendorf, Hamburg, Germany

²⁰⁰Harvard Medical School, Boston, USA

²⁰¹National Institute on Aging, Bethesda, USA

²⁰²School of Medicine, University of 3 Tampere, Tampere, Finland

²⁰³Vall d'Hebron Research Institute, Barcelona, Spain

²⁰⁴Department of Twin Research and Genetic Epidemiology, King's College London, UK

²⁰⁵Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol

²⁰⁶Max Planck Institute of Psychiatry, Munich, Germany

²⁰⁷Danish Headache Center, Dept. of Neurology, Department of Neurology, Rigshospitalet, Denmark

²⁰⁸Headache Research Group, Universitat Autònoma de Barcelona, Barcelona, Barcelona

²⁰⁹Sutter Health, Sacramento, USA

²¹⁰Department of Medicine, University of Turku, Turku, Finland

²¹¹Population Health Research Institute, St George's University of London, London, UK

, 23andMe Research Team

Michelle Agee¹², Babak Alipanahi¹², Adam Auton¹², Robert Bell¹², Katarzyna Bryc¹², Sarah Elson¹², Pierre Fontanillas¹², Nicholas Furlotte¹², Karl Heilbron¹², David Hinds¹², Karen Huber¹², Aaron Kleinman¹², Nadia Litterman¹², Jennifer McCreight¹², Matthew McIntyre¹², Joanna Mountain¹², Elizabeth Noblin¹², Carrie Northover¹², Steven Pitts¹², J. Sathirapongsasuti¹², Olga Sazonova¹², Janie Shelton¹², Suyash Shringarpure¹², Chao Tian¹², Joyce Tung¹², Vladimir Vacic¹², Catherine Wilson¹²

, Leo Brueggeman¹³, Gerome Breen^{14,15}, Cynthia M. Bulik^{1,9,16}, Ernest Arenas², Jens Hjerling-Leffler^{2,*}, Patrick F. Sullivan^{1,17,*}

¹Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-17177 Stockholm, Sweden

²Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-17177 Stockholm, Sweden

³UCL Institute of Neurology, Queen Square, London, UK

⁴Division of Brain Sciences, Department of Medicine, Imperial College, London, UK

⁵UK Dementia Research Institute at Imperial College London

⁶Danish Headache Center, Dept. of Neurology, Copenhagen University Hospital, Glostrup, Denmark

⁷Institute of Biological Psychiatry, Copenhagen University Hospital MHC Sct. Hans, Roskilde, Denmark

⁸Novo Nordic Foundations Center for Protein Research, Copenhagen University, Denmark

⁹Department of Psychiatry, University of North Carolina at Chapel Hill, North Carolina, US

¹⁰School of Psychology, Curtin University, Perth, Australia

¹¹Division of Paediatrics, School of Medicine, The University of Western Australia, Perth, Australia

¹²23andMe, Inc., Mountain View, CA, 94041, USA

¹³Department of Psychiatry, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, Iowa

¹⁴Institute of Psychiatry, MRC Social, Genetic and Developmental Psychiatry Centre, King's College London, UK

¹⁵National Institute for Health Research Biomedical Research Centre, South London and Maudsley National Health Service Trust, London, UK

¹⁶Department of Nutrition, University of North Carolina, Chapel Hill, NC, 27599-7264, USA

¹⁷Departments of Genetics, University of North Carolina, Chapel Hill, NC, 27599-7264, USA

These authors contributed equally to this work.

Abstract

Genome-wide association studies (GWAS) have discovered hundreds of loci associated with complex brain disorders but it remains unclear in which cell types these loci are active. Here we integrate GWAS results with single-cell transcriptomic data from the entire mouse nervous system to systematically identify cell types underlying brain complex traits. We show that psychiatric disorders are predominantly associated with projecting excitatory and inhibitory neurons. Neurological diseases were associated with different cell types, which is consistent with other lines of evidence. Notably, Parkinson's disease was not only genetically associated with cholinergic and monoaminergic neurons (which include dopaminergic neurons) but also with enteric neurons and oligodendrocytes. Using post-mortem brain transcriptomic data, we confirmed alterations in these cells, even at the earliest stages of disease progression. Our study provides an important framework for understanding the cellular basis of complex brain maladies, and reveals an unexpected role of oligodendrocytes in Parkinson's disease.

Introduction

Understanding the genetic basis of complex brain disorders is critical for developing rational therapeutics. In the last decade, GWAS have identified thousands of highly significant loci ¹⁻⁴. However, interpretation of GWAS remains challenging. First, >90% of the identified variants are located in non-coding regions ⁵, complicating precise identification of risk genes. Second, extensive linkage disequilibrium present in the human genome confounds efforts to pinpoint causal variants. Finally, it remains unclear in which tissues and cell types these variants are active, and how they disrupt specific biological networks to impact disease risk.

Functional genomic studies from brain are now seen as critical for interpretation of GWAS findings as they can identify functional regions (e.g., open chromatin, enhancers, transcription factor binding sites) and target genes (via chromatin interactions and eQTLs) ⁶. Gene regulation varies substantially across tissues and cell types ^{7,8}, and hence it is critical to perform functional genomic studies in empirically identified cell types or tissues.

Multiple groups have developed strategies to identify tissues associated with complex traits ⁹⁻¹³, but few have focused on the identification of salient cell types within a tissue.

Furthermore, previous studies used a small number of cell types derived from one or few different brain regions ^{3,11-17}. For example, we recently showed that, among 24 brain cell

types, four types of neurons were consistently associated with schizophrenia¹¹. We were explicit that this conclusion was limited by the relatively few brain regions studied; other cell types from unsampled regions could conceivably contribute to the disorder.

Here, we integrate a wider range of gene expression data – tissues across the human body and single-cell gene expression data from an entire nervous system – to identify tissues and cell types underlying a large number of complex traits (Fig. 1a,b). We find that psychiatric and cognitive traits are generally associated with similar cell types whereas neurological disorders are associated with different cell types. Notably, we show that Parkinson's disease is associated with cholinergic and monoaminergic neurons, enteric neurons and oligodendrocytes, providing new clues into its etiology.

Results

Association of traits with tissues using bulk RNA-seq

Our goal was to use GWAS results to identify relevant tissues and cell types. Our primary focus was human phenotypes whose etiopathology is based in the central nervous system. We thus obtained 18 sets of GWAS summary statistics for brain-related complex traits. For comparison, we included GWAS summary statistics for 8 diseases and traits with large sample sizes whose etiopathology is not rooted in the central nervous system (Methods).

We first aimed to identify human tissues showing enrichment for genetic associations using bulk-tissue RNA-seq (37 tissues) from GTEx⁷. To robustly identify tissues implied by these 26 GWAS, we used two approaches (MAGMA¹⁸ and LDSC^{12,19}) which employ different assumptions (Methods). For both methods, we tested whether the 10% most specific genes in each tissue were enriched in genetic associations with the different traits (Fig. 1b).

Examination of non-brain traits found, as expected, associations with salient tissues. For example, as shown in Fig. 1d and Supplementary Table 1, inflammatory bowel disease was strongly associated with immune tissues (blood, spleen) and alimentary tissues impacted by the disease (small intestine and colon). Lung and adipose tissue were also significantly associated with inflammatory bowel disease, possibly because of the high specificity of immune genes in these two tissues (Extended Data Figure 1). Type 2 diabetes was associated with the pancreas, while hemoglobin A1C, which is used to diagnose type 2 diabetes and monitor glycemic controls in diabetic patients, was associated with the pancreas, liver and stomach (Fig. 1d). Stroke and coronary artery disease were most associated with blood vessels and waist to hip ratio was most associated with adipose tissue (Fig. 1d and Supplementary Fig. 1).

For brain-related traits (Fig. 1c, Supplementary Fig. 1 and Supplementary Table 1), 13 of 18 traits were significantly associated with one or more GTEx brain regions. For example, schizophrenia, intelligence, educational attainment, neuroticism, BMI and MDD were most significantly associated with brain cortex, frontal cortex or anterior cingulate cortex, while Parkinson's disease was most significantly associated with the substantia nigra (as expected) and spinal cord (Fig. 1c). Alzheimer's disease was associated with tissues with prominent roles in immunity (blood and spleen) consistent with other studies^{20–22}, but also with the

substantia nigra and spinal cord, while stroke was associated with blood vessel (consistent with a role of arterial pathology in stroke)²³.

In conclusion, we show that tissue-level gene expression allows identification of relevant tissues for complex traits, indicating that our methodology is suitable to explore trait-gene expression associations at the cell type level.

Association of brain complex traits with cell types

We leveraged gene expression data from 39 broad categories of cell types from the mouse central and peripheral nervous system²⁴ to systematically map brain-related traits to cell types (Fig. 2a, Extended Data Figure 2). Our use of mouse data to inform human genetic findings was carefully considered (see Discussion).

As in our previous study of schizophrenia based on a small number of brain regions¹¹, we found the strongest signals for telencephalon projecting neurons (i.e. excitatory neurons from the cortex, hippocampus and amygdala), telencephalon projecting inhibitory neurons (i.e. medium spiny neurons from the striatum) and telencephalon inhibitory neurons (Fig. 2a and Supplementary Table 2). We also found that other types of neurons were associated with schizophrenia albeit less significantly (e.g., dentate gyrus granule neurons). Other psychiatric and cognitive traits had similar cellular association patterns to schizophrenia (Extended Data Figure 2,3 and Supplementary Table 2). We did not observe significant associations with immune or vascular cells for any psychiatric disorders or cognitive traits.

Neurological disorders generally implicated fewer cell types, possibly because neurological GWAS had lower signal than GWAS of cognitive, anthropometric, and psychiatric traits (Supplementary Fig. 2). Consistent with the genetic correlations (Supplementary Note), the pattern of associations for neurological disorders was distinct from psychiatric disorders (Extended Data Figure 2,3), reflecting that neurological disorders have minimal functional overlap with psychiatric disorders²⁵.

Stroke was significantly associated with vascular smooth muscle cells (Fig. 2a) consistent with an important role of vascular processes for this trait. Alzheimer's disease had the strongest signal in microglia, as reported previously^{10,16,26}, but the association did not survive multiple testing correction.

We found that Parkinson's disease was significantly associated with cholinergic and monoaminergic neurons (Fig. 2a). This cluster consists of neurons (Supplementary Table 3) that are known to degenerate in Parkinson's disease²⁷⁻²⁹, such as dopaminergic neurons from the substantia nigra (the hallmark of Parkinson's disease), but also serotonergic and glutamatergic neurons from the raphe nucleus³⁰, noradrenergic neurons³¹, as well as neurons from afferent nuclei in the pons³² and the medulla (the brain region associated with the earliest lesions in Parkinson's disease²⁷). In addition, hindbrain neurons and peptidergic neurons were also significantly associated with Parkinson's disease (with LDSC only). Interestingly, we also found that enteric neurons were significantly associated with Parkinson's disease (Fig. 2a), which is consistent with Braak's hypothesis, which postulates that Parkinson's disease could start in the gut and travel to the brain via the vagus nerve

^{33,34}. Furthermore, we found that oligodendrocytes (mainly sampled in the midbrain, medulla, pons, spinal cord and thalamus, Supplementary Fig. 3) were significantly associated with Parkinson's disease, indicating a strong glial component to the disorder. This finding was unexpected but consistent with the strong association of the spinal cord at the tissue level (Fig. 1c), as the spinal cord contains the highest proportion of oligodendrocytes (71%) in the nervous system²⁴. Altogether, these findings provide genetic evidence for a role of enteric neurons, cholinergic and monoaminergic neurons, as well as oligodendrocytes in Parkinson's disease etiology.

Neuronal prioritization in the mouse central nervous system

A key goal of this study was to prioritize specific cell types for follow-up experimental studies. As our metric of gene expression specificity was computed based on all cell types in the nervous system, it is possible that the most specific genes in a given cell type capture genes that are shared within a high level category of cell types (e.g. neurons). To rule out this possibility, we computed new specificity metrics based only on neurons from the central nervous system (CNS). We then tested whether the top 10% most specific genes for each CNS neuron were enriched in genetic association for the brain related traits that had a significant association with a CNS neuron (13/18) in our initial analysis.

Using the CNS neuron gene expression specificity metrics, we observed a reduction in the number of neuronal cell types associated with the different traits (Extended Data Figure 4), suggesting that some of the signal was driven by core neuronal genes. However, we found that multiple neuronal cell types remained associated with a number of traits. For example, we found that telencephalon projecting excitatory and projecting inhibitory neurons were strongly associated with schizophrenia, bipolar disorder, educational attainment and intelligence using both LDSC and MAGMA. Similarly, telencephalon projecting excitatory neurons were significantly associated with BMI, neuroticism, MDD, autism and anorexia using one of the two methods, while hindbrain neurons and cholinergic and monoaminergic neurons remained significantly associated with Parkinson's disease.

Altogether, these results suggest that specific types of CNS neurons can be prioritized for follow-up experimental studies for multiple traits.

Trait-cell type associations conditioning on other traits

As noted above, the pattern of associations of psychiatric and cognitive traits were highly correlated across the 39 different cell types tested (Extended Data Figure 3). For example, the Spearman rank correlation of cell type associations ($-\log_{10}P$) between schizophrenia and intelligence was 0.96 (0.94 for educational attainment) as both traits had the strongest signal in telencephalon projecting excitatory neurons and little signal in immune or vascular cells. In addition, we observed that genes driving the association signal in the top cell types of the two traits were enriched in relatively similar GO terms involving neurogenesis and synaptic processes (Supplementary Note). We evaluated two possible explanations for these findings: (a) schizophrenia and intelligence are both associated with the same genes that are specifically expressed in the same cell types or (b) schizophrenia and intelligence are associated with different sets of genes that are both specific to the same cell types. Given

that these two traits have a significant negative genetic correlation ($r_g = -0.22$, from GWAS results alone) (Supplementary Table 4), we hypothesized that the strong overlap in cell type associations for schizophrenia and intelligence was due to the second explanation.

To evaluate these hypotheses, we tested whether the 10% most specific genes for each cell type were enriched in genetic associations for schizophrenia controlling for the gene-level genetic association of intelligence using MAGMA (and vice versa) and found that the pattern of associations were largely unaffected. Similarly, we found that controlling for educational attainment had little effect on the schizophrenia associations and vice versa (Extended Data Figure 5). In other words, genes driving the cell type associations of schizophrenia appear to be distinct from genes driving the cell types associations of cognitive traits.

Trait-cell type associations conditioning on cell types

Many neuronal cell types passed our stringent significance threshold for multiple brain traits (Fig. 2a). This could be because gene expression profiles are highly correlated across cell types and/or because many cell types are independently associated with the different traits. In order to address this, we performed univariate conditional analysis using MAGMA, testing whether cell type associations remained significant after controlling for the 10% most specific genes from other cell types (Supplementary Table 5). We observed that multiple cell types were independently associated with age at menarche, anorexia, autism, bipolar, BMI, educational attainment, intelligence, MDD, neuroticism and schizophrenia (Supplementary Fig. 4). As in our previous study¹¹, we found that the association between schizophrenia and telencephalon projecting inhibitory neurons (i.e. medium spiny neurons) was independent from telencephalon projecting excitatory neurons (i.e. pyramidal neurons). For Parkinson's disease, enteric neurons, oligodendrocytes and cholinergic and monoaminergic neurons were independently associated with the disorder (Fig. 2b), suggesting that these three different cell types play an independent role in the etiology of the disorder.

Replication in other single-cell RNA-seq datasets

To assess the robustness of our results, we repeated these analyses in independent datasets. A key caveat is that these other datasets did not sample the entire nervous system as in the analyses above.

First, we used a single-cell RNA-seq dataset that identified 88 broad categories of cell types from 9 mouse brain regions³⁵. We found similar patterns of association in this external dataset (Fig. 3a, Extended Data Figure 6 and Supplementary Table 6). Notably, for schizophrenia, we strongly replicated associations with neurons from the cortex, hippocampus and striatum. We also observed similar cell type associations for other psychiatric and cognitive traits (Fig. 3a, Extended Data Figure 6,7). For neurological disorders, we found that stroke was significantly associated with mural cells while Alzheimer's disease was significantly associated with microglia (Extended Data Figure 6). The associations of Parkinson's disease with neurons from the substantia nigra and oligodendrocytes were significant at a nominal level in this dataset ($P=0.006$ for neurons from the substantia nigra, $P=0.027$ for oligodendrocytes using LDSC). By computing gene

expression specificity within neurons, we replicated our findings that neurons from the cortex can be prioritized for multiple traits (schizophrenia, bipolar, educational attainment, intelligence, BMI, neuroticism, MDD, anorexia) (Extended Data Figure 8).

Second, we reanalyzed these GWAS datasets using our previous dataset¹¹ (24 cell types from five mouse brain regions, Fig. 3b, Extended Data Figure 9 and Supplementary Table 7). We again found strong associations of pyramidal neurons from the somatosensory cortex, pyramidal neurons from the CA1 region of the hippocampus (both corresponding to telencephalon projecting excitatory neurons in our main dataset), and medium spiny neurons from the striatum (corresponding to telencephalon projecting inhibitory neurons) with psychiatric and cognitive traits. MDD and autism were most associated with neuroblasts, while intracranial volume was most associated with neural progenitors. The association of dopaminergic adult neurons with Parkinson's disease was significant at a nominal level using LDSC ($P=0.01$), while oligodendrocytes did not replicate in this dataset, perhaps because they were not sampled from the regions affected by the disorder (i.e. spinal cord, pons, medulla or midbrain). A within-neuron analysis again found that projecting excitatory (i.e. pyramidal CA1) and projecting inhibitory neurons (i.e. medium spiny neurons) can be prioritized for multiple traits (schizophrenia, bipolar, intelligence, educational attainment, BMI). In addition, neuroblasts could be prioritized for MDD and neural progenitors could be prioritized for intracranial volume (Extended Data Figure 10).

Third, we evaluated a human dataset consisting of 15 different cell types from cortex and hippocampus³⁶ (Fig. 4a and Supplementary Table 8). We replicated our findings with psychiatric and cognitive traits being associated with pyramidal neurons (excitatory) and interneurons (inhibitory) from the somatosensory cortex and hippocampus. We also replicated the association of Parkinson's disease with oligodendrocytes (enteric neurons and cholinergic and monoaminergic neurons were not sampled in this dataset). No cell types reached our significance threshold using specificity metrics computed within-neurons, possibly because of similarities in the transcriptomes of neurons from the cortex and hippocampus.

Fourth, we evaluated a human dataset consisting of 31 different cell types from 3 different brain regions (visual cortex, frontal cortex and cerebellum) (Fig. 4b and Supplementary Table 9)³⁷. We found that schizophrenia, educational attainment, neuroticism and BMI were associated with excitatory neurons, while bipolar was associated with both excitatory and inhibitory neurons. As observed previously^{10,16,26}, Alzheimer's disease was significantly associated with microglia. Oligodendrocytes were not significantly associated with Parkinson's disease in this dataset, again possibly because the spinal cord, pons, medulla and midbrain were not sampled. No cell types reached our significance threshold using specificity metrics computed within neurons in this dataset.

Validation of oligodendrocyte pathology in Parkinson

We investigated the role of oligodendrocytes in Parkinson's disease. First, we confirmed the association of oligodendrocytes with Parkinson's disease by combining evidence across all datasets (Fisher's combined probability test, $P=2.5 \times 10^{-7}$ using MAGMA and 6.3×10^{-3} using LDSC) (Supplementary Table 2 and Supplementary Fig. 5). In addition, oligodendrocytes

remained significantly associated with Parkinson's disease after conditioning on the top neuronal cell type in each dataset ($P=1.2 \times 10^{-7}$, Fisher's combined probability test).

Third, we tested whether genes with rare variants associated with Parkinsonism (Supplementary Table 10) were specifically expressed in cell types from the mouse nervous system (Method). As for the common variant, we found the strongest enrichment for cholinergic and monoaminergic neurons (Supplementary Table 11). However, we did not observe any significant enrichments for oligodendrocytes or enteric neurons for these genes.

Fourth, we applied EWCE¹⁰ to test whether genes that are up/down-regulated in human post-mortem Parkinson's disease brains (from six separate cohorts) were enriched in cell types located in the substantia nigra and ventral midbrain (Fig. 5). Three of the studies had a case-control design and measured gene expression in: (a) the substantia nigra of 9 controls and 16 cases³⁸, (b) the medial substantia nigra of 8 controls and 15 cases³⁹, and (c) the lateral substantia nigra of 7 controls and 9 cases³⁹. In all three studies, downregulated genes in Parkinson's disease were specifically enriched in dopaminergic neurons (consistent with the loss of this particular cell type in disease), while upregulated genes were significantly enriched in cells from the oligodendrocyte lineage. This suggests that an increased oligodendrocyte activity or proliferation could play a role in Parkinson's disease etiology. Surprisingly, no enrichment was observed for microglia, despite recent findings^{40,41}.

We also analyzed gene expression data from post-mortem human brains which had been scored by neuropathologists for their Braak stage⁴². Differential expression was calculated between brains with Braak scores of zero (controls) and brains with Braak scores of 1—2, 3—4 and 5—6. At the latter stages (Braak scores 3—4 and 5—6), downregulated genes were specifically expressed in dopaminergic neurons, while upregulated genes were specifically expressed in oligodendrocytes (Fig. 5), as observed in the case-control studies. Moreover, Braak stage 1 and 2 are characterized by little degeneration in the substantia nigra and, consistently, we found that downregulated genes were not enriched in dopaminergic neurons at this stage. Notably, upregulated genes were already strongly enriched in oligodendrocytes at Braak Stages 1-2. These results not only support the genetic evidence indicating that oligodendrocytes may play a causal role in Parkinson's disease, but indicate that their involvement precedes the emergence of pathological changes in the substantia nigra.

Discussion

In this study, we used gene expression data from cells sampled from the entire nervous system to systematically map cell types to GWAS results from multiple psychiatric, cognitive, and neurological complex phenotypes.

We note several limitations. First, we emphasize that we can implicate a particular cell type but it is premature to exclude cell types for which we do not have data¹¹. Second, we used gene expression data from mouse to understand human phenotypes. We believe our approach is appropriate for several reasons. (A) Crucially, the key findings replicated in human data. (B) Single-cell RNA-seq is achievable in mouse but difficult in human neurons (where single-nuclei RNA-seq is typical^{36,37,43,44}). In brain, differences between single-cell

and single-nuclei RNA-seq are important as transcripts that are missed by sequencing nuclei are important for psychiatric disorders¹¹, and we previously showed that dendritically-transported transcripts are specifically depleted from nuclei datasets¹¹ (confirmed in four additional datasets, Supplementary Fig. 6). (C) Correlations in gene expression for cell type across species is high (median correlation 0.68, Supplementary Fig. 7), and as high or higher than correlations across methods within cell type and species (single-cell vs single-nuclei RNA-seq, median correlation 0.6)⁴⁵. (D) We only evaluated protein-coding genes with 1:1 orthologs between mouse and human, which are highly conserved. (E) We previously showed that gene expression data cluster by cell type and not by species¹¹, indicating broad conservation of core brain cellular functions across species. (F) We used a large number of genes to map cell types to traits (~1500 genes for each cell type), minimizing potential bias due to individual genes differentially expressed across species. (G) If there were strong differences in cell type gene expression between mouse and human, we would not expect that specific genes in mouse cell types would be enriched in genetic associations with human disorders. However, it remains possible that some cell types have different gene expression patterns between mouse and human, are only present in one species, have a different function or are involved in different brain circuits.

A third limitation is that gene expression data were from adolescent mice. Although many psychiatric and neurological disorders have onsets in adolescence, some have onsets earlier (autism) or later (Alzheimer's and Parkinson's disease). It is thus possible that some cell types are vulnerable at specific developmental times. Data from studies mapping cell types across brain development and aging are required to resolve this issue.

We found that psychiatric traits implicated largely similar cell types. These biological findings are consistent with genetic and epidemiological evidence of a general psychopathy factor underlying diverse psychiatric disorders^{25,46,47}. Although intelligence and educational attainment implicated similar cell types, conditional analyses showed that the same cell types were implicated for different reasons. This suggests that different sets of genes highly specific to the same cell types contribute independently to schizophrenia and cognitive traits.

Our findings for neurological disorders were strikingly different from psychiatric disorders. In contrast to previous studies that either did not identify any cell type associations with Parkinson's disease⁴⁸ or identified significant associations with cell types from the adaptive immune system⁴¹, we found that cholinergic and monoaminergic neurons (which include dopaminergic neurons), enteric neurons and oligodendrocytes were significantly and independently associated with the disease. Our findings suggest that dopaminergic neuron loss in Parkinson's disease (the hallmark of the disease) is at least partly due to intrinsic biological mechanisms.

Interestingly, enteric neurons were also associated with Parkinson's disease. This result is in line with prior evidence implicating the gut in Parkinson's disease. Notably, dopaminergic defects and Lewy bodies (i.e. abnormal aggregates of proteins enriched in α -synuclein) are found in the enteric nervous system of patients affected by Parkinson's disease^{49,50}. In addition, Lewy bodies have been observed in patients up to 20 years prior to their diagnosis

⁵¹ and sectioning of the vagus nerve (which connects the enteric nervous system to the central nervous system) was shown to reduce the risk of developing Parkinson's disease ⁵². Therefore, our results linking enteric neurons with Parkinson's disease provides new genetic evidence for Braak's hypothesis ³³.

The association of oligodendrocytes with Parkinson's disease was more unexpected. A possible explanation is that this association could be due to a related disorder (e.g., multiple system atrophy, characterized by Parkinsonism and accumulation of α -synuclein in glial cytoplasmic inclusions ⁵³). However, this explanation is unlikely as multiple system atrophy is a very rare disorder; hence, only a few patients could have been included in the Parkinson's disease GWAS. In addition, misdiagnosis is unlikely to have led to the association of Parkinson's disease with oligodendrocytes. Indeed, we found a high genetic correlation between self-reported diagnosis from the 23andMe cohort and a previous GWAS of clinically-ascertained Parkinson's disease ⁵⁴.

We did not find an association of oligodendrocytes with Parkinsonism for genes affected by rare variants. This result may reflect etiological differences between sporadic and familial forms of the disease or low statistical power. Prior evidence has suggested an involvement of oligodendrocytes in Parkinson's disease. For example, α -synuclein-containing inclusions have been reported in oligodendrocytes in Parkinson's disease brains ⁵⁵. These inclusions ("coiled bodies") are typically found throughout the brainstem nuclei and fiber tracts ⁵⁶. Although the presence of coiled bodies in oligodendrocytes is a common, specific, and well-documented neuropathological feature of Parkinson's disease, the importance of this cell type and its early involvement in disease has not been fully recognized. Our findings suggest that alterations in oligodendrocytes occur at an early stage of disease, which precedes neurodegeneration in the substantia nigra, arguing for a key role of this cell type in Parkinson's disease etiology.

Methods

GWAS results

Our goal was to use GWAS results to identify relevant tissues and cell types. Our primary focus was human phenotypes whose etiopathology is based in the central nervous system. We thus obtained 18 sets of GWAS summary statistics from European samples for brain-related complex traits. These were selected because they had at least one genome-wide significant association (as of 2018; e.g., Parkinson's disease, schizophrenia, and IQ). For comparison, we included GWAS summary statistics for 8 diseases and traits with large sample sizes whose etiopathology is not rooted in the central nervous system (e.g., type 2 diabetes). The selection of these conditions allowed contrasts of tissues and cells highlighted by our primary interest in brain phenotypes with non-brain traits.

The phenotypes were: schizophrenia ¹, educational attainment ², intelligence ¹⁴, body mass index ⁴, bipolar disorder ⁵⁷, neuroticism ³, major depressive disorder ⁵⁸, age at menarche ⁵⁹, autism ⁶⁰, migraine ⁶¹, amyotrophic lateral sclerosis ⁶², ADHD ⁶³, Alzheimer's disease ²¹, age at menopause ⁶⁴, coronary artery disease ⁶⁵, height ⁴, hemoglobin A1c ⁶⁶, hippocampal volume ⁶⁷, inflammatory bowel disease ⁶⁸, intracranial volume ⁶⁹, stroke ⁷⁰, type 2 diabetes

mellitus ⁷¹, type 2 diabetes adjusted for BMI ⁷¹, waist-hip ratio adjusted for BMI ⁷², and anorexia nervosa ⁷³.

For Parkinson's disease, we performed an inverse variance-weighted meta-analysis ⁷⁴ using summary statistics from Nalls et al. ⁵⁴ (9,581 cases, 33,245 controls) and summary statistics from 23andMe (12,657 cases, 941,588 controls). We found a very high genetic correlation (r_g) ⁷⁵ between results from these cohorts ($r_g=0.87$, $s.e.=0.068$) with little evidence of sample overlap (LDSC bivariate intercept=0.0288, $s.e.=0.0066$). The P-values from the meta-analysis strongly deviated from the expected (Supplementary Fig. 8) but was consistent with polygenicity (LDSC intercept=1.0048, $s.e.=0.008$) rather than uncontrolled inflation ⁷⁵. In this new meta-analysis, we identified 61 independent loci associated with Parkinson's disease (49 reported previously ¹⁷ and 12 novel) (Supplementary Fig. 9). The 10,000 most associated SNPs from the 23andMe cohort are available in Supplementary Table 12.

Gene expression data

We collected publicly available single-cell RNA-seq data from different studies. The core dataset of our analysis is a study that sampled more than 500K single cells from the entire mouse nervous system (19 regions) and identified 39 broad categories (level 4) and 265 refined cell types (level 5) ²⁴. The 39 cell types expressed a median of 16417 genes, had a median UMI total count of ~8.6M and summed the expression of a median of 1501 single cells (Supplementary Table 13). The replication datasets were: 1) a mouse study that sampled 690K single cells from 9 brain regions (frontal cortex, striatum, globus pallidus externus/nucleus basalis, thalamus, hippocampus, posterior cortex, entopeduncular nucleus/subthalamic nucleus, substantia nigra/ventral tegmental area, and cerebellum) and identified 565 cell types ⁷⁶ (note that we averaged the UMI counts by broad categories of cell type in each brain region, resulting in 88 different cell types); 2) our prior mouse study of ~10K cells from 5 different brain regions (and samples enriched for oligodendrocytes, dopaminergic neurons, serotonergic neurons and cortical parvalbuminergic interneurons) that identified 24 broad categories and 149 refined cell types ¹¹; 3) a study that sampled 19,550 nuclei from frozen adult human post-mortem hippocampus and prefrontal cortex and identified 16 cell types ³⁶; 4) a study that generated 36,166 single-nuclei expression measurements (after quality control) from the human visual cortex, frontal cortex and cerebellum ³⁷. We also obtained bulk tissues RNA-seq gene expression data from 53 tissues from the GTEx consortium ⁷ (v8, median across samples).

Gene expression data processing

All datasets were processed uniformly. First we computed the mean expression for each gene in each cell type from the single-cell expression data (if this statistics was not provided by the authors). We used the pre-computed median expression across individuals for the GTEx dataset and excluded tissues that were not sampled in at least 100 individuals, non-natural tissues (e.g. EBV-transformed lymphocytes) and testis (outlier using hierarchical clustering). We then averaged the expression of tissues by organ (with the exception of brain tissues) resulting in gene expression profiles of a total of 37 tissues. For all datasets, we filtered out any genes with non-unique names, genes not expressed in any cell types, non-protein coding genes, and, for mouse datasets, genes that had no expert curated 1:1 orthologs

between mouse and human (Mouse Genome Informatics, The Jackson laboratory, version 11/22/2016). Gene expression was then scaled to a total of 1M UMIs (or transcript per million (TPM)) for each cell type/tissue. We then calculated a metric of gene expression specificity by dividing the expression of each gene in each cell type by the total expression of that gene in all cell types, leading to values ranging from 0 to 1 for each gene (0: meaning that the gene is not expressed in that cell type, 0.6: that 60% of the total expression of that gene is performed in that cell type, 1: that 100% of the expression of that gene is performed in that cell type). The top 10% most specific genes (Supplementary Table 14,15) in each tissue/cell type partially overlapped for related tissues/cell types, did not overlap for unrelated tissue/cell types and allowed to cluster related tissues/cell types as expected (Supplementary Fig. 10,11).

MAGMA primary and conditional analyses

MAGMA (v1.06b)¹⁸ is a software for gene-set enrichment analysis using GWAS summary statistics. Briefly, MAGMA computes a gene-level association statistic by averaging P-values of SNPs located around a gene (taking into account LD structure). The gene-level association statistic is then transformed to a Z-value. MAGMA can then be used to test whether a gene set is a predictor of the gene-level association statistic of the trait (Z-value) in a linear regression framework. MAGMA accounts for a number of important covariates such as gene size, gene density, mean sample size for tested SNPs per gene, the inverse of the minor allele counts per gene and the log of these metrics.

For each GWAS summary statistics, we excluded any SNPs with INFO score <0.6, with MAF < 1% or with estimated odds ratio > 25 or smaller than 1/25, the MHC region (chr6:25-34 Mb) for all GWAS and the *APOE* region (chr19:45020859–45844508) for the Alzheimer's GWAS. We set a window of 35kb upstream to 10kb downstream of the gene coordinates to compute gene-level association statistics and used the European reference panel from the phase 3 of the 1000 genomes project⁷⁷ as the reference population. For each trait, we then used MAGMA to test whether the 10% most specific gene in each tissue/cell type was associated with gene-level genetic association with the trait. Only genes with at least 1TPM or 1 UMI per million in the tested cell type were used for this analysis. The significance level of the different cell types was highly correlated with the effect size of the cell type (Supplementary Fig. 12) with values ranging between 0.999 and 1 across the 18 brain related traits in the Zeisel et al. dataset²⁴. The significance threshold was set to a 5% false discovery rate across all tissues/cell types and traits within each dataset.

MAGMA can also perform conditional analyses given its linear regression framework. We used MAGMA to test whether cell types were associated with a specific trait conditioning on the gene-level genetic association of another trait (Z-value from MAGMA .out file) or to look for associations of cell types conditioning on the 10% most specific genes from other cell types by adding these variables as covariate in the model.

To test whether MAGMA was well-calibrated, we randomly permuted the gene labels of the schizophrenia gene-level association statistic file a thousand times. We then looked for association between the 10% most specific genes in each cell type and the randomized gene-level schizophrenia association statistics. We observed that MAGMA was slightly

conservative with less than 5% of the random samplings having a P-value <0.05 (Supplementary Fig. 13).

We also evaluated the effect of varying window sizes (for the SNPs to gene assignment step of MAGMA) on the schizophrenia cell type associations strength ($-\log_{10}(P)$). We observed strong Pearson correlations in cell type associations strength ($-\log_{10}(P)$) across the different window sizes tested (Supplementary Fig. 14). Our selected window size (35kb upstream to 10 kb downstream) had Pearson correlations ranging from 0.94 to 0.98 with the other window sizes, indicating that our results are robust to this parameter.

In a recent paper, Watanabe et al.⁷⁸ introduced a different methodology to test for cell type – complex trait association based on MAGMA. Their proposed methodology tests for a positive relationship between gene expression levels and gene-level genetic associations with a complex trait (using all genes). Their method uses the average expression of each gene in all cell types in the dataset as a covariate. We examined the method of Watanabe et al. in detail, and decided against its use for multiple reasons.

First, Watanabe et al. hypothesize that genes with higher levels of expression should be more associated with a trait. In extended discussions among our team (which include multiple neuroscientists), we have strong reservations about the appropriateness and biological meaningfulness of this hypothesis; it is a strong requirement and is at odds with decades of neuroscience research where molecules expressed at low levels can have profound biological impact. For instance, many cell-type specific genes that are disease relevant are expressed at moderate levels (e.g., *Drd2* is in the 10% most specific genes in telencephalon projecting inhibitory neurons but in the bottom 30% of expression levels). Our method does not make this hypothesis.

Second, the method of Watanabe et al. corrects for the average expression of all cell types in a dataset. This practice is, in our view, problematic as it necessarily forces dependence on the composition of a scRNA-seq dataset. For instance, if a dataset consists mostly of neurons, this amounts to correcting for neuronal expression and necessarily erodes power to detect trait enrichment in neurons. Alternatively, if a dataset is composed mostly of non-neuronal cells, this will impact the detection of enrichment in non-neuronal cells.

Third, preliminary results indicate that the method of Watanabe et al. is sensitive to scaling. As different cell types express different numbers of genes, scaling to the same total read counts affects the average gene expression across cell types (which they use as a covariate), leading to different results with different choices of scaling factors (e.g., scaling to 10k vs 1 million reads). Our method is not liable to this issue.

LD score regression analysis

We used partitioned LD score regression⁷⁹ to test whether the top 10% most specific genes of each cell type (based on our specificity metric described above) were enriched in heritability for the diverse traits. Only genes with at least 1TPM or 1 UMI per million in the tested cell type were used for this analysis. In order to capture most regulatory elements that could contribute to the effect of the region on the trait, we extended the gene coordinates by

100kb upstream and by 100kb downstream of each gene as previously¹². SNPs located in 100kb regions surrounding the top 10% most specific genes in each cell type were added to the baseline model (consisting of 53 different annotations) independently for each cell type (one file for each cell type). We then selected the coefficient z-score p-value as a measure of the association of the cell type with the traits. The significance threshold was set to a 5% false discovery rate across all tissues/cell types and traits within each dataset. All plots show the mean $-\log_{10}(P)$ of partitioned LDscore regression and MAGMA. All results for MAGMA or LDSC are available in supplementary data files.

We evaluated the effect of varying window sizes and varying the percentage of most specific genes on the schizophrenia cell type associations strength ($-\log_{10}P$). We observed strong Pearson correlations in cell type associations strength ($-\log_{10}P$) across the different percentage and window sizes tested (Supplementary Fig. 15). Our selected window size (100 kb upstream to 100 kb downstream, top 10% most specific genes) had Pearson correlations ranging from 0.96 to 1 with the other window sizes and percentage, indicating that our results are robust to these parameters.

MAGMA vs LDSC ranking

In order to test whether the cell type ranking obtained using MAGMA and LDSC in the Zeisel et al. dataset²⁴ were similar, we computed the Spearman rank correlation of the cell types association strength ($-\log_{10}P$) between the two methods for each complex trait. The Spearman rank correlation was strongly correlated with λ_{GC} (a measure of the deviation of the GWAS test statistics from the expected) (Spearman correlation = 0.89) (Supplementary Fig. 16) and with the average number of cell types below our stringent significance threshold (Spearman correlation = 0.92), indicating that the overall ranking of the cell types is very similar between the two methods, provided that the GWAS is well powered (Supplementary Fig. 17). In addition, we found that λ_{GC} was strongly correlated with the strength of association of the top tissue ($-\log_{10}P$) (Spearman correlation = 0.88) (Supplementary Fig. 18), as well as with the effect size (beta) of the top tissue (Spearman correlation = 0.9), indicating that cell type – trait associations are stronger for well powered GWAS. The significance level ($-\log_{10}P$) was also strongly correlated with the effect size (Spearman correlation = 0.996) (Supplementary Fig. 18) for the top cell type of each trait.

Dendritic depletion analysis

This analysis was performed as previously described¹¹. In brief, all datasets were reduced to a set of six common cell types: pyramidal neurons, interneurons, astrocytes, microglia and oligodendrocyte precursors. Specificity was recalculated using only these six cell types. Comparisons were then made between pairs of datasets (denoted in the graph with the format 'X versus Y'). The difference in specificity for a set of dendrite enriched genes is calculated between the datasets. Differences in specificity are also calculated for random sets of genes selected from the background gene set. The probability and z-score for the difference in specificity for the dendritic genes is thus estimated. Dendritically enriched transcripts were obtained from Supplementary Table 10 of Cajigas et al.⁸⁰. For the KI dataset¹¹, we used S1 pyramidal neurons. For the Zeisel 2018 dataset²⁴ we used all ACTE* cells as astrocytes, TEGLU* as pyramidal neurons, TEINH* as interneurons, OPC as

oligodendrocyte precursors and MGL* as microglia. For the Saunders dataset³⁵, we used all Neuron.Slc17a7 cell types from FC, HC or PC as pyramidal neurons; all Neuron.Gad1Gad2 cell types from FC, HC or PC as interneurons; Polydendrocyte as OPCs; Astrocyte as astrocytes, and Microglia as microglia. The Lake datasets both came from a single publication³⁷ which had data from frontal cortex, visual cortex and cerebellum. The cerebellum data was not used here. Data from frontal and visual cortices were analyzed separately. All other datasets were used as described in our previous publication¹¹. The code and data for this analysis are available as an R package (see code availability below).

GO term enrichment

We tested whether genes that were highly specific to a trait-associated cell type (top 20% in a given cell type) AND highly associated with the genetics of the traits (top 10% MAGMA gene-level genetic association) were enriched in biological functions using the *topGOR* package⁸¹. As background, we used genes that were highly specific to the cell type (top 20%) OR highly associated with the trait (top 10% MAGMA gene-level genetic association).


Parkinson's disease rare variant enrichments

We searched the literature for genes associated with Parkinsonism on the basis of rare and familial mutations. We found 66 genes (listed in Supplementary Table 10). We used linear regression to test whether the z-scaled specificity metric (per cell type) of the 66 genes were greater than 0 in the different cell types.

Parkinson's disease post-mortem transcriptomes


The Moran dataset³⁹ was obtained from GEO (accession GSE8397). Processing of the U133a and U133b Cel files was done separately. The data was read in using the ReadAffy function from the R affy package⁸², then Robust Multi-array Averaging (RMA) was applied. The U133a and U133b array expression data were merged after applying RMA. Probe annotations and mapping to HGNC symbols was done using the biomaRt R package⁸³. Differential expression analysis was performed using limma⁸⁴ taking age and gender as covariates. The Lesnick dataset³⁸ was obtained from GEO (accession GSE7621). Data was processed as for the Moran dataset: however, age was not available to use as a covariate. The Disjkstra dataset⁴² was obtained from GEO (accession GSE49036) and processed as above: the gender and RIN values were used as covariates. As the transcriptome datasets measured gene expression in the substantia nigra, we only kept cell types that are present in the substantia nigra or ventral midbrain for our EWCE¹⁰ analysis. We computed a new specificity matrix based on the substantia nigra or ventral midbrain cells from the Zeisel dataset (level 5) using EWCE¹⁰. The EWCE analysis was performed on the 500 most up or down regulated genes using 10,000 bootstrapping replicates.

Extended Data




Extended Data Fig. 1. Enrichment of immune genes in GTEx tissues.

Enrichment pvalues of genes belonging to the GO term “Immune System Process” in the 10% most specific genes in each tissue. The one-sided pvalues were computed using linear regression, testing whether the average specificity metric of the gene set was higher than 0 (z-scaled specificity metrics per tissue). The GO term was selected because it is the most associated with inflammatory bowel disease using MAGMA.




Extended Data Fig. 2. Associations of brain related traits with cell types from the entire mouse nervous system.

Associations of the top 15 most associated cell types are shown. The mean strength of association (-log₁₀P) of MAGMA and LDSC is shown and the bar color indicates whether the cell type is significantly associated with both methods, one method or none (significance threshold: 5% false discovery rate).




Extended Data Fig. 3. Correlation in cell type associations across traits.


The Spearman rank correlations between the cell types associations across traits ($-\log_{10}P$) are shown. SCZ (schizophrenia), EDU (educational attainment), INT (intelligence), BMI (body mass index), BIP (bipolar disorder), NEU (neuroticism), PAR (Parkinson’s disease), MDD (Major depressive disorder), MEN (age at menarche), ICV (intracranial volume), ASD (autism spectrum disorder), STR (stroke), AN (anorexia nervosa), MIG (migraine), ALS (amyotrophic lateral sclerosis), ADHD (attention deficit hyperactivity disorder), ALZ (Alzheimer’s disease), HIP (hippocampal volume).



Extended Data Fig. 4. Associations of brain related traits with neurons from the central nervous system.
 Associations of the 15 most associated neurons from the central nervous system (CNS) are shown. The specificity metrics were computed only using neurons from the CNS. The mean strength of association ($-\log_{10}P$) of MAGMA and LDSC is shown and the bar color indicates whether the cell type is significantly associated with both methods, one method or none (significance threshold: 5% false discovery rate).




Extended Data Fig. 5. Associations of cell types with schizophrenia/cognitive traits conditioning on gene-level genetic association of cognitive traits/schizophrenia. MAGMA association strength for each cell type before and after conditioning on gene-level genetic association for another trait. The black bar represents the significance threshold (5% false discovery rate). SCZ (schizophrenia), INT (intelligence), EDU (educational attainment).




Extended Data Fig. 6. Replication of cell type – trait associations in 88 cell types from 9 different brain regions.

The mean strength of association ($-\log_{10}P$) of MAGMA and LDSC is shown for the 15 top cell types for each trait. The bar color indicates whether the cell type is significantly associated with both methods, one method or none (significance threshold: 5% false discovery rate).




Extended Data Fig. 7. Correlation in cell type associations across traits in a replication data set (88 cell types, 9 brain regions).

Spearman rank correlations for cell types associations ($-\log_{10}P$) across traits are shown. SCZ (schizophrenia), EDU (educational attainment), INT (intelligence), BMI (body mass index), BIP (bipolar disorder), NEU (neuroticism), PAR (Parkinson’s disease), MDD (Major depressive disorder), MEN (age at menarche), ICV (intracranial volume), ASD (autism spectrum disorder), STR (stroke), AN (anorexia nervosa), MIG (migraine), ALS (amyotrophic lateral sclerosis), ADHD (attention deficit hyperactivity disorder), ALZ (Alzheimer’s disease), HIP (hippocampal volume).



Extended Data Fig. 8. Associations of brain related traits with neurons from 9 different brain regions.

Trait – neuron association are shown for neurons of the 9 different brain regions. The specificity metrics were computed only using neurons. The mean strength of association ($-\log_{10}P$) of MAGMA and LDSC is shown and the bar color indicates whether the cell type is significantly associated with both methods, one method or none (significance threshold: 5% false discovery rate).



Extended Data Fig. 9. Top associated cell types with brain related traits among 24 cell types from 5 different brain regions.

The mean strength of association ($-\log_{10}P$) of MAGMA and LDSC is shown for the 15 top cell types for each trait. The bar color indicates whether the cell type is significantly associated with both methods, one method or none (significance threshold: 5% false discovery rate).



Extended Data Fig. 10. Top associated neurons with brain related traits among 16 neurons from 5 different brain regions. The specificity metrics were computed only using neurons. The mean strength of association (-log₁₀P) of MAGMA and LDSC is shown for the top 15 cell types for each trait. The bar color indicates whether the cell type is significantly associated with both methods, one method or none (significance threshold= 5% false discovery rate).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Julien Broyois^{#1}, Nathan G. Skene^{#2,3,4,5}, Thomas Folkmann Hansen^{6,7,8},
 Lisette J. A. Kogelman⁶, Hunna J. Watson^{9,10,11}, Zijing Liu^{4,5}, Eating Disorders
 Working Group of the Psychiatric Genomics Consortium
 Roger Adan^{18,19,20}, Lars Alfredsson²¹, Tetsuya Ando²², Ole Andreassen²³,
 Jessica Baker⁹, Andrew Bergen^{24,25}, Wade Berrettini²⁶, Andreas
 Birgegård^{27,28}, Joseph Boden²⁹, Ilka Boehm³⁰, Claudette Boni³¹, Vesna
 Boraska Perica^{32,33}, Harry Brandt³⁴, Gerome Breen^{14,15}, Julien Broyois¹,
 Katharina Buehren³⁵, Cynthia Bulik^{1,9,16}, Roland Burghardt³⁶, Matteo
 Cassina³⁷, Sven Cichon³⁸, Maurizio Clementi³⁷, Jonathan Coleman^{14,15}, Roger
 Cone³⁹, Philippe Courtet⁴⁰, Steven Crawford³⁴, Scott Crow⁴¹, James
 Crowley^{17,27}, Unna Danner¹⁹, Oliver Davis^{42,43}, Martina de Zwaan⁴⁴, George
 Dedoussis⁴⁵, Daniela Degortes⁴⁶, Janiece DeSocio⁴⁷, Danielle Dick⁴⁸, Dimitris
 Dikeos⁴⁹, Christian Dina^{50,51}, Monika Dmitrzak-Weglaz⁵², Elisa Docampo
 Martinez^{53,54,55}, Laramie Duncan⁵⁶, Karin Egberts⁵⁷, Stefan Ehrlich³⁰, Geòrgia
 Escaramís^{53,54,55}, Tõnu Esko^{58,59}, Xavier Estivill^{53,54,55,60}, Anne Farmer¹⁴,
 Angela Favaro⁴⁶, Fernando Fernández-Aranda^{61,62}, Manfred Fichter^{63,64},
 Krista Fischer⁵⁸, Manuel Föcker⁶⁵, Lenka Foretova⁶⁶, Andreas
 Forstner^{38,67,68,69,70}, Monica Forzan³⁷, Christopher Franklin³², Steven
 Gallinger⁷¹, Héléna Gaspar^{14,15}, Ina Giegling⁷², Johanna Giuranna⁶⁵, Paola
 Giusti-Rodríguez¹⁷, Fragiskos Gonidakis⁷³, Scott Gordon⁷⁴, Philip
 Gorwood^{31,75}, Monica Gratacos Mayora^{53,54,55}, Jakob Grove^{76,77,78,79},
 Sébastien Guillaume⁴⁰, Yiran Guo⁸⁰, Hakon Hakonarson^{80,81}, Katherine
 Halmi⁸², Ken Hanscombe⁸³, Konstantinos Hatzikotoulas³², Joanna Hauser⁸⁴,
 Johannes Hebebrand⁶⁵, Sietske Helder^{14,85}, Anjali Henders⁸⁶, Stefan
 Herms^{38,70}, Beate Herpertz-Dahlmann³⁵, Wolfgang Herzog⁸⁷, Anke Hinney⁶⁵,
 L. John Horwood²⁹, Christopher Hübel^{14,1}, Laura Huckins^{32,88}, James
 Hudson⁸⁹, Hartmut Imgart⁹⁰, Hidetoshi Inoko⁹¹, Vladimir Janout⁹², Susana
 Jiménez-Murcia^{61,62}, Craig Johnson⁹³, Jennifer Jordan^{94,95}, Antonio Julià⁹⁶,
 Anders Juréus¹, Gursharan Kalsi¹⁴, Deborah Kaminská⁹⁷, Allan Kaplan⁹⁸,
 Jaakko Kaprio^{99,100}, Leila Karhunen¹⁰¹, Andreas Karwautz¹⁰², Martien
 Kas^{18,103}, Walter Kaye¹⁰⁴, James Kennedy⁹⁸, Martin Kennedy¹⁰⁵, Anna Keski-
 Rahkonen⁹⁹, Kirsty Kiezebrink¹⁰⁶, Youl-Ri Kim¹⁰⁷, Katherine Kirk⁷⁴, Lars
 Klareskog¹⁰⁸, Kelly Klump¹⁰⁹, Gun Peggy Knudsen¹¹⁰, Maria La Via⁹, Mikael
 Landén^{1,20}, Janne Larsen^{77,111,112}, Stephanie Le Hellard^{113,114,115}, Virpi
 Leppä¹, Robert Levitan¹¹⁶, Dong Li⁸⁰, Paul Lichtenstein¹, Lisa Lilienfeld¹¹⁷,
 Bochao Danae Lin¹⁸, Jolanta Lissowska¹¹⁸, Jurjen Luykx¹⁸, Pierre
 Magistretti^{119,120}, Mario Maj¹²¹, Katrin Mannik^{58,122}, Sara Marsal⁹⁶, Christian
 Marshall¹²³, Nicholas Martin⁷⁴, Manuel Mattheisen^{76,27,28,124}, Morten
 Mattingsdal²³, Sara McDevitt^{125,126}, Peter McGuffin¹⁴, Sarah Medland⁷⁴,
 Andres Metspalu^{58,127}, Ingrid Meulenbelt¹²⁸, Nadia Micali^{129,130}, James
 Mitchell¹³¹, Karen Mitchell¹³², Palmiero Monteleone¹³³, Alessio Maria
 Monteleone¹²¹, Grant Montgomery^{74,86,134}, Preben Bo Mortensen^{77,111,112},
 Melissa Munn-Chernoff⁹, Benedetta Nacmias¹³⁵, Marie Navratilova⁶⁶, Claes

Norring^{27,28}, Ioanna Ntalla⁴⁵, Catherine Olsen⁷⁴, Roel Ophoff^{18,136}, Julie O'Toole¹³⁷, Leonid Padyukov¹⁰⁸, Aarno Palotie^{59,100,138}, Jacques Pantel³¹, Hana Papezova⁹⁷, Richard Parker⁷⁴, John Pearson¹³⁹, Nancy Pedersen¹, Liselotte Petersen^{77,111,112}, Dalila Pinto⁸⁸, Kirstin Purves¹⁴, Raquel Rabionet^{140,141,142}, Anu Raevuori⁹⁹, Nicolas Ramoz³¹, Ted Reichborn-Kjennerud^{110,143}, Valdo Ricca^{135,144}, Samuli Ripatti¹⁴⁵, Stephan Ripke^{146,147,148}, Franziska Ritschel^{30,149}, Marion Roberts¹⁴, Alessandro Rotondo¹⁵⁰, Dan Rujescu^{63,72}, Filip Rybakowski¹⁵¹, Paolo Santonastaso¹⁵², André Scherag¹⁵³, Stephen Scherer¹⁵⁴, Ulrike Schmidt¹⁴, Nicholas Schork¹⁵⁵, Alexandra Schosser¹⁵⁶, Jochen Seitz³⁵, Lenka Slachtova¹⁵⁷, P. Eline Slagboom¹²⁸, Margarita Slof-Op 't Landt^{158,159}, Agnieszka Slopian¹⁶⁰, Sandro Sorbi^{135,161}, Michael Strober^{162,163}, Garret Stuber^{9,164}, Patrick Sullivan^{1,17}, Beata Wi tkowska¹⁶⁵, Jin Szatkiewicz¹⁷, Ioanna Tachmazidou³², Elena Tenconi⁴⁶, Laura Thornton⁹, Alfonso Tortorella^{166,167}, Federica Tozzi¹⁶⁸, Janet Treasure¹⁴, Artemis Tsitsika¹⁶⁹, Marta Tyszkiewicz-Nwafor¹⁵¹, Konstantinos Tziouvas¹⁷⁰, Annemarie van Elburg^{19,171}, Eric van Furth^{158,159}, Tracey Wade¹⁷², Gudrun Wagner¹⁰², Esther Walton³⁰, Hunna Watson^{9,10,11}, Thomas Werge¹⁷³, David Whiteman⁷⁴, Elisabeth Widen¹⁰⁰, D. Blake Woodside^{174,175}, Shuyang Yao¹, Zeynep Yilmaz^{9,17}, Eleftheria Zeggini^{32,176}, Stephanie Zerwas⁹, Stephan Zipfel¹⁷⁷

¹⁸Brain Center Rudolf Magnus, Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands

¹⁹Center for Eating Disorders Rintveld, Altrecht Mental Health Institute, Zeist, The Netherlands

²⁰Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

²¹Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

²²Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan

²³NORMENT KG Jebsen Centre, Division of Mental Health and Addiction, University of Oslo, Oslo University Hospital, Oslo, Norway

²⁴BioRealm, LLC, Walnut, California, US

²⁵Oregon Research Institute, Eugene, Oregon, US

²⁶Department of Psychiatry, Center for Neurobiology and Behavior, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, US

²⁷Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

²⁸Center for Psychiatry Research, Stockholm Health Care Services, Stockholm City Council, Stockholm, Sweden

- ²⁹Christchurch Health and Development Study, University of Otago, Christchurch, New Zealand**
- ³⁰Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany**
- ³¹INSERM U894, Centre of Psychiatry and Neuroscience, Paris, France**
- ³²Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK**
- ³³Department of Medical Biology, School of Medicine, University of Split, Split, Croatia**
- ³⁴The Center for Eating Disorders at Sheppard Pratt, Baltimore, Maryland, US**
- ³⁵Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany**
- ³⁶Klinikum Frankfurt/Oder, Frankfurt, Germany**
- ³⁷Clinical Genetics Unit, Department of Woman and Child Health, University of Padova, Padova, Italy**
- ³⁸Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland**
- ³⁹Life Sciences Institute and Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, US**
- ⁴⁰Department of Emergency Psychiatry and Post-Acute Care, CHRU Montpellier, University of Montpellier, Montpellier, France**
- ⁴¹Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, US**
- ⁴²MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK**
- ⁴³School of Social and Community Medicine, University of Bristol, Bristol, UK**
- ⁴⁴Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany**
- ⁴⁵Department of Nutrition and Dietetics, Harokopio University, Athens, Greece**
- ⁴⁶Department of Neurosciences, University of Padova, Padova, Italy**
- ⁴⁷College of Nursing, Seattle University, Seattle, Washington, US**
- ⁴⁸Department of Psychology, Virginia Commonwealth University, Richmond, Virginia, US**
- ⁴⁹Department of Psychiatry, Athens University Medical School, Athens University, Athens, Greece**
- ⁵⁰L'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France**

- ⁵¹L'institut du thorax, CHU Nantes, Nantes, France**
- ⁵²Department of Psychiatric Genetics, Poznan University of Medical Sciences, Poznan, Poland**
- ⁵³Barcelona Institute of Science and Technology, Barcelona, Spain**
- ⁵⁴Universitat Pompeu Fabra, Barcelona, Spain**
- ⁵⁵Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain**
- ⁵⁶Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, US**
- ⁵⁷Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Centre for Mental Health, Würzburg, Germany**
- ⁵⁸Estonian Genome Center, University of Tartu, Tartu, Estonia**
- ⁵⁹Program in Medical and Population Genetics, Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, US**
- ⁶⁰Genomics and Disease, Bioinformatics and Genomics Programme, Centre for Genomic Regulation, Barcelona, Spain**
- ⁶¹Department of Psychiatry, University Hospital of Bellvitge –IDIBELL and CIBERobn, Barcelona, Spain**
- ⁶²Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain**
- ⁶³Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University (LMU), Munich, Germany**
- ⁶⁴Schön Klinik Roseneck affiliated with the Medical Faculty of the University of Munich (LMU), Munich, Germany**
- ⁶⁵Department of Child and Adolescent Psychiatry, University Hospital Essen, University of Duisburg-Essen, Essen, Germany**
- ⁶⁶Department of Cancer, Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic**
- ⁶⁷Institute of Human Genetics, University of Bonn School of Medicine & University Hospital Bonn, Bonn, Germany**
- ⁶⁸Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany**
- ⁶⁹Department of Psychiatry (UPK), University of Basel, Basel, Switzerland**
- ⁷⁰Department of Biomedicine, University of Basel, Basel, Switzerland**

- ⁷¹Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, Canada**
- ⁷²Department of Psychiatry, Psychotherapy and Psychosomatics, Martin Luther University of Halle-Wittenberg, Halle, Germany**
- ⁷³1st Psychiatric Department, National and Kapodistrian University of Athens, Medical School, Eginition Hospital, Athens, Greece**
- ⁷⁴QIMR Berghofer Medical Research Institute, Brisbane, Australia**
- ⁷⁵CMME (Groupe Hospitalier Sainte-Anne), Paris Descartes University, Paris, France**
- ⁷⁶Department of Biomedicine, Aarhus University, Aarhus, Denmark**
- ⁷⁷The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark**
- ⁷⁸Centre for Integrative Sequencing, iSEQ, Aarhus University, Aarhus, Denmark**
- ⁷⁹Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark**
- ⁸⁰Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, US**
- ⁸¹Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, US**
- ⁸²Department of Psychiatry, Weill Cornell Medical College, New York, New York, US**
- ⁸³Department of Medical and Molecular Genetics, King's College London, Guy's Hospital, London, UK**
- ⁸⁴Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland**
- ⁸⁵Zorg op Orde, Leidschendam, The Netherlands**
- ⁸⁶Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia**
- ⁸⁷Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany**
- ⁸⁸Department of Psychiatry, and Genetics and Genomics Sciences, Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, New York, US**
- ⁸⁹Biological Psychiatry Laboratory, McLean Hospital/Harvard Medical School, Boston, Massachusetts, US**
- ⁹⁰Eating Disorders Unit, Parklandklinik, Bad Wildungen, Germany**

- ⁹¹Department of Molecular Life Science, Division of Basic Medical Science and Molecular Medicine, School of Medicine, Tokai University, Isehara, Japan**
- ⁹²Faculty of Health Sciences, Palacky University, Olomouc, Czech Republic**
- ⁹³Eating Recovery Center, Denver, Colorado, US**
- ⁹⁴Department of Psychological Medicine, University of Otago, Christchurch, New Zealand**
- ⁹⁵Canterbury District Health Board, Christchurch, New Zealand**
- ⁹⁶Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain**
- ⁹⁷Department of Psychiatry, First Faculty of Medicine, Charles University, Prague, Czech Republic**
- ⁹⁸Center for Addiction and Mental Health, Department of Psychiatry, Institute of Medical Science, University of Toronto, Toronto, Canada**
- ⁹⁹Department of Public Health, University of Helsinki, Helsinki, Finland**
- ¹⁰⁰Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland**
- ¹⁰¹Institute of Public Health and Clinical Nutrition, Department of Clinical Nutrition, University of Eastern Finland, Kuopio, Finland**
- ¹⁰²Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria**
- ¹⁰³Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands**
- ¹⁰⁴Department of Psychiatry, University of California San Diego, San Diego, California, US**
- ¹⁰⁵Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand**
- ¹⁰⁶Health Services Research Unit, University of Aberdeen, Aberdeen, UK**
- ¹⁰⁷Department of Psychiatry, Seoul Paik Hospital, Inje University, Seoul, Korea**
- ¹⁰⁸Rheumatology Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden**
- ¹⁰⁹Department of Psychology, Michigan State University, East Lansing, Michigan, US**
- ¹¹⁰Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway**

- ¹¹¹National Centre for Register-Based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark**
- ¹¹²Centre for Integrated Register-based Research (CIRRAU), Aarhus University, Aarhus, Denmark**
- ¹¹³Department of Clinical Science, K.G. Jebsen Centre for Psychosis Research, Norwegian Centre for Mental Disorders Research (NORMENT), University of Bergen, Bergen, Norway**
- ¹¹⁴Dr. Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway**
- ¹¹⁵Department of Clinical Medicine, Laboratory Building, Haukeland University Hospital, Bergen, Norway**
- ¹¹⁶Institute of Medical Science, University of Toronto, Toronto, Canada**
- ¹¹⁷American School of Professional Psychology, Argosy University, Northern Virginia, Arlington, Virginia, US**
- ¹¹⁸Department of Cancer Epidemiology and Prevention, M Skłodowska-Curie Cancer Center - Oncology Center, Warsaw, Poland**
- ¹¹⁹BESE Division, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia**
- ¹²⁰Department of Psychiatry, University of Lausanne-University Hospital of Lausanne (UNIL-CHUV), Lausanne, Switzerland**
- ¹²¹Department of Psychiatry, University of Campania "Luigi Vanvitelli", Naples, Italy**
- ¹²²Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland**
- ¹²³Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada**
- ¹²⁴Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany**
- ¹²⁵Department of Psychiatry, University College Cork, Cork, Ireland**
- ¹²⁶Eist Linn Adolescent Unit, Bessborough, Health Service Executive South, Cork, Ireland**
- ¹²⁷Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia**
- ¹²⁸Molecular Epidemiology Section (Department of Medical Statistics), Leiden University Medical Centre, Leiden, The Netherlands**
- ¹²⁹Department of Psychiatry, Faculty of Medicine, University of Geneva, Geneva, Switzerland**

- ¹³⁰Division of Child and Adolescent Psychiatry, Geneva University Hospital, Geneva, Switzerland**
- ¹³¹Department of Psychiatry and Behavioral Science, University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota, US**
- ¹³²National Center for PTSD, VA Boston Healthcare System, Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, US**
- ¹³³Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy**
- ¹³⁴Queensland Brain Institute, University of Queensland, Brisbane, Australia**
- ¹³⁵Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy**
- ¹³⁶Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, US**
- ¹³⁷Kartini Clinic, Portland, Oregon, US**
- ¹³⁸Center for Human Genome Research at the Massachusetts General Hospital, Boston, Massachusetts, US**
- ¹³⁹Biostatistics and Computational Biology Unit, University of Otago, Christchurch, New Zealand**
- ¹⁴⁰Saint Joan de Déu Research Institute, Saint Joan de Déu Barcelona Children's Hospital, Barcelona, Spain**
- ¹⁴¹Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain**
- ¹⁴²Department of Genetics, Microbiology and Statistics, University of Barcelona, Barcelona, Spain**
- ¹⁴³Institute of Clinical Medicine, University of Oslo, Oslo, Norway**
- ¹⁴⁴Department of Health Science, University of Florence, Florence, Italy**
- ¹⁴⁵Department of Biometry, University of Helsinki, Helsinki, Finland**
- ¹⁴⁶Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, US**
- ¹⁴⁷Stanley Center for Psychiatric Research, Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, US**
- ¹⁴⁸Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin, Berlin, Germany**
- ¹⁴⁹Eating Disorders Research and Treatment Center, Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany**

- ¹⁵⁰Department of Psychiatry, Neurobiology, Pharmacology, and Biotechnologies, University of Pisa, Pisa, Italy**
- ¹⁵¹Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland**
- ¹⁵²Department of Neurosciences, Padua Neuroscience Center, University of Padova, Padova, Italy**
- ¹⁵³Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital, Jena, Germany**
- ¹⁵⁴Department of Genetics and Genomic Biology, The Hospital for Sick Children, Toronto, Canada**
- ¹⁵⁵J. Craig Venter Institute (JCVI), La Jolla, California, US**
- ¹⁵⁶Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria**
- ¹⁵⁷Department of Pediatrics and Center of Applied Genomics, First Faculty of Medicine, Charles University, Prague, Czech Republic**
- ¹⁵⁸Center for Eating Disorders Ursula, Rivierduinen, Leiden, The Netherlands**
- ¹⁵⁹Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands**
- ¹⁶⁰Department of Child and Adolescent Psychiatry, Poznan University of Medical Sciences, Poznan, Poland**
- ¹⁶¹IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy**
- ¹⁶²Department of Psychiatry and Biobehavioral Science, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, US**
- ¹⁶³David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, US**
- ¹⁶⁴Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US**
- ¹⁶⁵Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland**
- ¹⁶⁶Department of Psychiatry, University of Naples SUN, Naples, Italy**
- ¹⁶⁷Department of Psychiatry, University of Perugia, Perugia, Italy**
- ¹⁶⁸Brain Sciences Department, Stremble Ventures, Limassol, Cyprus**
- ¹⁶⁹Adolescent Health Unit, Second Department of Pediatrics, "P. & A. Kyriakou" Children's Hospital, University of Athens, Athens, Greece**

- ¹⁷⁰Pediatric Intensive Care Unit, "P. & A. Kyriakou" Children's Hospital, University of Athens, Athens, Greece**
- ¹⁷¹Faculty of Social and Behavioral Sciences, Utrecht University, Utrecht, The Netherlands**
- ¹⁷²School of Psychology, Flinders University, Adelaide, Australia**
- ¹⁷³Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark**
- ¹⁷⁴Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Canada**
- ¹⁷⁵Toronto General Hospital, Toronto, Canada**
- ¹⁷⁶Institute of Translational Genomics, Helmholtz Zentrum München, Neuherberg, Germany**
- ¹⁷⁷Department of Internal Medicine VI, Psychosomatic Medicine and Psychotherapy, University Medical Hospital Tuebingen, Tuebingen, Germany**
, International Headache Genetics Consortium
Verner Anttila¹⁷⁸, Ville Artto¹⁷⁹, Andrea Carmine Belin¹⁸⁰, Irene de Boer¹⁸¹, Dorret I Boomsma¹⁸², Sigrid Børte¹⁸³, Daniel I Chasman¹⁸⁴, Lynn Cherkas¹⁸⁵, Anne Francke Christensen¹⁸⁶, Bru Cormand¹⁸⁷, Ester Cuenca-Leon¹⁷⁸, George Davey-Smith¹⁸⁸, Martin Dichgans¹⁸⁹, Cornelia van Duijn¹⁹⁰, Tonu Esko⁵⁸, Ann Louise Esserlind¹⁹¹, Michel Ferrari¹⁸¹, Rune R. Frants¹⁸¹, Tobias Freilinger¹⁹², Nick Furlotte¹⁹³, Padhraig Gormley¹⁷⁸, Lyn Griffiths¹⁹⁴, Eija Hamalainen¹⁹⁵, Thomas Folkmann Hansen⁶, Marjo Hiekkala¹⁹⁶, M Arfan Ikram¹⁹⁰, Andres Ingason¹⁹⁷, Marjo-Riitta Järvelin¹⁹⁸, Risto Kajanne¹⁹⁵, Mikko Kallela¹⁷⁹, Jaakko Kaprio^{99,100}, Mari Kaunisto¹⁹⁶, Lisette J.A. Kogelman⁶, Christian Kubisch¹⁹⁹, Mitja Kurki¹⁷⁸, Tobias Kurth²⁰⁰, Lenore Launer²⁰¹, Terho Lehtimäki²⁰², Davor Lesell¹⁹⁹, Lannie Ligthart¹⁸², Nadia Litterman¹⁹³, Arn van den Maagdenberg¹⁸¹, Alfons Macaya²⁰³, Rainer Malik¹⁸⁹, Massimo Mangino²⁰⁴, George McMahon²⁰⁵, Bertram Muller-Myhsok²⁰⁶, Benjamin M. Neale¹⁷⁸, Carrie Northover¹⁹³, Dale R. Nyholt¹⁹⁴, Jes Olesen²⁰⁷, Aarno Palotie^{59,100,138}, Priit Palta¹⁹⁵, Linda Pedersen¹⁸³, Nancy Pedersen¹, Danielle Posthuma¹⁸², Patricia Pozo-Rosich²⁰⁸, Alice Pressman²⁰⁹, Olli Raitakari²¹⁰, Markus Schürks²⁰⁰, Celia Sintas¹⁸⁷, Kari Stefansson¹⁹⁷, Hreinn Stefansson¹⁹⁷, Stacy Steinberg¹⁹⁷, David Strachan²¹¹, Gisela Terwindt¹⁸¹, Marta Vila-Pueyo²⁰³, Maija Wessman¹⁹⁶, Bendik S. Winsvold¹⁸³, Huiying Zhao¹⁹⁴, John Anker Zwart¹⁸³
- ¹⁷⁸Broad Institute of MIT and Harvard, Cambridge, USA**
- ¹⁷⁹Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland**
- ¹⁸⁰Karolinska Institutet, Stockholm, Sweden**
- ¹⁸¹Leiden University Medical Centre, Leiden, The Netherlands**

- ¹⁸²VU University, Amsterdam, The Netherlands**
- ¹⁸³Oslo University Hospital and University of Oslo, Oslo, Norway**
- ¹⁸⁴Harvard Medical School, Cambridge, USA**
- ¹⁸⁵Department of Twin Research and Genetic Epidemiology, King's College London, London, UK**
- ¹⁸⁶Danish Headache Center, Copenhagen University Hospital, Copenhagen, Denmark**
- ¹⁸⁷University of Barcelona, Barcelona, Spain**
- ¹⁸⁸Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol, UK**
- ¹⁸⁹Institute for Stroke and Dementia Research, Munich, Germany**
- ¹⁹⁰Erasmus University Medical Centre, Rotterdam, The Netherlands**
- ¹⁹¹Danish Headache Center, Department of Neurology, Rigshospitalet, Denmark**
- ¹⁹²University of Tuebingen, Tuebingen, Germany**
- ¹⁹³23&Me Inc., Mountain View, USA**
- ¹⁹⁴Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia**
- ¹⁹⁵Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland**
- ¹⁹⁶Folkhälsan Institute of Genetics, Helsinki, Finland**
- ¹⁹⁷Decode genetics Inc., Reykjavik, Iceland**
- ¹⁹⁸University of Oulu, Biocenter Oulu, Finland**
- ¹⁹⁹University Medical Center Hamburg-Eppendorf, Hamburg, Germany**
- ²⁰⁰Harvard Medical School, Boston, USA**
- ²⁰¹National Institute on Aging, Bethesda, USA**
- ²⁰²School of Medicine, University of Tampere, Tampere, Finland**
- ²⁰³Vall d'Hebron Research Institute, Barcelona, Spain**
- ²⁰⁴Department of Twin Research and Genetic Epidemiology, King's College London, UK**
- ²⁰⁵Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol**
- ²⁰⁶Max Planck Institute of Psychiatry, Munich, Germany**

²⁰⁷Danish Headache Center, Dept. of Neurology, Department of Neurology, Rigshospitalet, Denmark

²⁰⁸Headache Research Group, Universitat Autònoma de Barcelona, Barcelona, Barcelona

²⁰⁹Sutter Health, Sacramento, USA

²¹⁰Department of Medicine, University of Turku, Turku, Finland

²¹¹Population Health Research Institute, St George's University of London, London, UK

, 23andMe Research Team

Michelle Agee¹², Babak Alipanahi¹², Adam Auton¹², Robert Bell¹², Katarzyna Bryc¹², Sarah Elson¹², Pierre Fontanillas¹², Nicholas Furlotte¹², Karl Heilbron¹², David Hinds¹², Karen Huber¹², Aaron Kleinman¹², Nadia Litterman¹², Jennifer McCreight¹², Matthew McIntyre¹², Joanna Mountain¹², Elizabeth Noblin¹², Carrie Northover¹², Steven Pitts¹², J. Sathirapongsasuti¹², Olga Sazonova¹², Janie Shelton¹², Suyash Shringarpure¹², Chao Tian¹², Joyce Tung¹², Vladimir Vacic¹², Catherine Wilson¹²

, Leo Brueggeman¹³, Gerome Breen^{14,15}, Cynthia M. Bulik^{1,9,16}, Ernest Arenas², Jens Hjerling-Leffler^{2,*}, Patrick F. Sullivan^{1,17,*}

Roger Adan^{18,19,20}, Lars Alfredsson²¹, Tetsuya Ando²², Ole Andreassen²³, Jessica Baker⁹, Andrew Bergen^{24,25}, Wade Berrettini²⁶, Andreas Birgegård^{27,28}, Joseph Boden²⁹, Ilka Boehm³⁰, Claudette Boni³¹, Vesna Boraska Perica^{32,33}, Harry Brandt³⁴, Gerome Breen^{14,15}, Julien Bryois¹, Katharina Buehren³⁵, Cynthia Bulik^{1,9,16}, Roland Burghardt³⁶, Matteo Cassina³⁷, Sven Cichon³⁸, Maurizio Clementi³⁷, Jonathan Coleman^{14,15}, Roger Cone³⁹, Philippe Courtet⁴⁰, Steven Crawford³⁴, Scott Crow⁴¹, James Crowley^{17,27}, Unna Danner¹⁹, Oliver Davis^{42,43}, Martina de Zwaan⁴⁴, George Dedoussis⁴⁵, Daniela Degortes⁴⁶, Janiece DeSocio⁴⁷, Danielle Dick⁴⁸, Dimitris Dikeos⁴⁹, Christian Dina^{50,51}, Monika Dmitrzak-Weglaz⁵², Elisa Docampo Martinez^{53,54,55}, Laramie Duncan⁵⁶, Karin Egberts⁵⁷, Stefan Ehrlich³⁰, Geòrgia Escaramís^{53,54,55}, Tõnu Esko^{58,59}, Xavier Estivill^{53,54,55,60}, Anne Farmer¹⁴, Angela Favaro⁴⁶, Fernando Fernández-Aranda^{61,62}, Manfred Fichter^{63,64}, Krista Fischer⁵⁸, Manuel Föcker⁶⁵, Lenka Foretova⁶⁶, Andreas Forstner^{38,67,68,69,70}, Monica Forzan³⁷, Christopher Franklin³², Steven Gallinger⁷¹, Héléna Gaspar^{14,15}, Ina Giegling⁷², Johanna Giuranna⁶⁵, Paola Giusti-Rodríguez¹⁷, Fragiskos Gonidakis⁷³, Scott Gordon⁷⁴, Philip Gorwood^{31,75}, Monica Gratacos Mayora^{53,54,55}, Jakob Grove^{76,77,78,79}, Sébastien Guillaume⁴⁰, Yiran Guo⁸⁰, Hakon Hakonarson^{80,81}, Katherine Halmi⁸², Ken Hanscombe⁸³, Konstantinos Hatzikotoulas³², Joanna Hauser⁸⁴, Johannes Hebebrand⁶⁵, Sietske Helder^{14,85}, Anjali Henders⁸⁶, Stefan Herms^{38,70}, Beate Herpertz-Dahlmann³⁵, Wolfgang Herzog⁸⁷, Anke Hinney⁶⁵, L. John Horwood²⁹, Christopher Hübel^{14,1}, Laura Huckins^{32,88}, James Hudson⁸⁹, Hartmut Imgart⁹⁰, Hidetoshi Inoko⁹¹, Vladimir Janout⁹², Susana Jiménez-Murcia^{61,62}, Craig Johnson⁹³, Jennifer Jordan^{94,95}, Antonio Juliá⁹⁶, Anders Juréus¹, Gursharan Kalsi¹⁴, Deborah Kaminská⁹⁷, Allan

Kaplan⁹⁸, Jaakko Kaprio^{99,100}, Leila Karhunen¹⁰¹, Andreas Karwautz¹⁰², Martien Kas^{18,103}, Walter Kaye¹⁰⁴, James Kennedy⁹⁸, Martin Kennedy¹⁰⁵, Anna Keski-Rahkonen⁹⁹, Kirsty Kiezebrink¹⁰⁶, Youl-Ri Kim¹⁰⁷, Katherine Kirk⁷⁴, Lars Klareskog¹⁰⁸, Kelly Klump¹⁰⁹, Gun Peggy Knudsen¹¹⁰, Maria La Via⁹, Mikael Landén^{1,20}, Janne Larsen^{77,111,112}, Stephanie Le Hellard^{113,114,115}, Virpi Leppä¹, Robert Levitan¹¹⁶, Dong Li⁸⁰, Paul Lichtenstein¹, Lisa Lilienfeld¹¹⁷, Bochao Danae Lin¹⁸, Jolanta Lissowska¹¹⁸, Jurjen Luykx¹⁸, Pierre Magistretti^{119,120}, Mario Maj¹²¹, Katrin Mannik^{58,122}, Sara Marsal⁹⁶, Christian Marshall¹²³, Nicholas Martin⁷⁴, Manuel Mattheisen^{76,27,28,124}, Morten Mattingsdal²³, Sara McDevitt^{125,126}, Peter McGuffin¹⁴, Sarah Medland⁷⁴, Andres Metspalu^{58,127}, Ingrid Meulenbelt¹²⁸, Nadia Micali^{129,130}, James Mitchell¹³¹, Karen Mitchell¹³², Palmiero Monteleone¹³³, Alessio Maria Monteleone¹²¹, Grant Montgomery^{74,86,134}, Preben Bo Mortensen^{77,111,112}, Melissa Munn-Chernoff⁹, Benedetta Nacmias¹³⁵, Marie Navratilova⁶⁶, Claes Norring^{27,28}, Ioanna Ntalla⁴⁵, Catherine Olsen⁷⁴, Roel Ophoff^{18,136}, Julie O'Toole¹³⁷, Leonid Padyukov¹⁰⁸, Aarno Palotie^{59,100,138}, Jacques Pantel³¹, Hana Papezova⁹⁷, Richard Parker⁷⁴, John Pearson¹³⁹, Nancy Pedersen¹, Liselotte Petersen^{77,111,112}, Dalila Pinto⁸⁸, Kirstin Purves¹⁴, Raquel Rabionet^{140,141,142}, Anu Raevuori⁹⁹, Nicolas Ramoz³¹, Ted Reichborn-Kjennerud^{110,143}, Valdo Ricca^{135,144}, Samuli Ripatti¹⁴⁵, Stephan Ripke^{146,147,148}, Franziska Ritschel^{30,149}, Marion Roberts¹⁴, Alessandro Rotondo¹⁵⁰, Dan Rujescu^{63,72}, Filip Rybakowski¹⁵¹, Paolo Santonastaso¹⁵², André Scherag¹⁵³, Stephen Scherer¹⁵⁴, Ulrike Schmidt¹⁴, Nicholas Schork¹⁵⁵, Alexandra Schosser¹⁵⁶, Jochen Seitz³⁵, Lenka Slachtova¹⁵⁷, P. Eline Slagboom¹²⁸, Margarita Slof-Op 't Landt^{158,159}, Agnieszka Slopian¹⁶⁰, Sandro Sorbi^{135,161}, Michael Strober^{162,163}, Garret Stuber^{9,164}, Patrick Sullivan^{1,17}, Beata Wi tkowska¹⁶⁵, Jin Szatkiewicz¹⁷, Ioanna Tachmazidou³², Elena Tenconi⁴⁶, Laura Thornton⁹, Alfonso Tortorella^{166,167}, Federica Tozzi¹⁶⁸, Janet Treasure¹⁴, Artemis Tsitsika¹⁶⁹, Marta Tyszkiewicz-Nwafor¹⁵¹, Konstantinos Tziouvas¹⁷⁰, Annemarie van Elburg^{19,171}, Eric van Furth^{158,159}, Tracey Wade¹⁷², Gudrun Wagner¹⁰², Esther Walton³⁰, Hunna Watson^{9,10,11}, Thomas Werge¹⁷³, David Whiteman⁷⁴, Elisabeth Widen¹⁰⁰, D. Blake Woodside^{174,175}, Shuyang Yao¹, Zeynep Yilmaz^{9,17}, Eleftheria Zeggini^{32,176}, Stephanie Zerwas⁹, Stephan Zipfel¹⁷⁷

Verner Anttila¹⁷⁸, Ville Artto¹⁷⁹, Andrea Carmine Belin¹⁸⁰, Irene de Boer¹⁸¹, Dorret I Boomsma¹⁸², Sigrid Børte¹⁸³, Daniel I Chasman¹⁸⁴, Lynn Cherkas¹⁸⁵, Anne Francke Christensen¹⁸⁶, Bru Cormand¹⁸⁷, Ester Cuenca-Leon¹⁷⁸, George Davey-Smith¹⁸⁸, Martin Dichgans¹⁸⁹, Cornelia van Duijn¹⁹⁰, Tonu Esko⁵⁸, Ann Louise Esserlind¹⁹¹, Michel Ferrari¹⁸¹, Rune R. Frants¹⁸¹, Tobias Freilinger¹⁹², Nick Furlotte¹⁹³, Padhraig Gormley¹⁷⁸, Lyn Griffiths¹⁹⁴, Eija Hamalainen¹⁹⁵, Thomas Folkmann Hansen⁶, Marjo Hiekkala¹⁹⁶, M Arfan Ikram¹⁹⁰, Andres Ingason¹⁹⁷, Marjo-Riitta Järvelin¹⁹⁸, Risto Kajanne¹⁹⁵, Mikko Kallela¹⁷⁹, Jaakko Kaprio^{99,100}, Mari Kaunisto¹⁹⁶, Lisette J.A. Kogelman⁶, Christian Kubisch¹⁹⁹, Mitja Kurki¹⁷⁸, Tobias Kurth²⁰⁰, Lenore Launer²⁰¹, Terho Lehtimäki²⁰², Davor Lessel¹⁹⁹, Lannie Ligthart¹⁸², Nadia Litterman¹⁹³, Arn van den Maagdenberg¹⁸¹, Alfons Macaya²⁰³, Rainer Malik¹⁸⁹, Massimo Mangino²⁰⁴, George McMahon²⁰⁵, Bertram Muller-Myhsok²⁰⁶, Benjamin M. Neale¹⁷⁸, Carrie Northover¹⁹³, Dale R. Nyholt¹⁹⁴, Jes

Olesen²⁰⁷, Aarno Palotie^{59,100,138}, Priit Palta¹⁹⁵, Linda Pedersen¹⁸³, Nancy Pedersen¹, Danielle Posthuma¹⁸², Patricia Pozo-Rosich²⁰⁸, Alice Pressman²⁰⁹, Olli Raitakari²¹⁰, Markus Schürks²⁰⁰, Celia Sintas¹⁸⁷, Kari Stefansson¹⁹⁷, Hreinn Stefansson¹⁹⁷, Stacy Steinberg¹⁹⁷, David Strachan²¹¹, Gisela Terwindt¹⁸¹, Marta Vila-Pueyo²⁰³, Maija Wessman¹⁹⁶, Bendik S. Winsvold¹⁸³, Huiying Zhao¹⁹⁴, John Anker Zwart¹⁸³

Michelle Agee¹², Babak Alipanahi¹², Adam Auton¹², Robert Bell¹², Katarzyna Bryc¹², Sarah Elson¹², Pierre Fontanillas¹², Nicholas Furlotte¹², Karl Heilbron¹², David Hinds¹², Karen Huber¹², Aaron Kleinman¹², Nadia Litterman¹², Jennifer McCreight¹², Matthew McIntyre¹², Joanna Mountain¹², Elizabeth Noblin¹², Carrie Northover¹², Steven Pitts¹², J. Sathirapongsasuti¹², Olga Sazonova¹², Janie Shelton¹², Suyash Shringarpure¹², Chao Tian¹², Joyce Tung¹², Vladimir Vacic¹², Catherine Wilson¹²

Affiliations

¹⁸Brain Center Rudolf Magnus, Department of Translational Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands

¹⁹Center for Eating Disorders Rintveld, Altrecht Mental Health Institute, Zeist, The Netherlands

²⁰Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

²¹Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden

²²Department of Behavioral Medicine, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan

²³NORMENT KG Jebsen Centre, Division of Mental Health and Addiction, University of Oslo, Oslo University Hospital, Oslo, Norway

²⁴BioRealm, LLC, Walnut, California, US

²⁵Oregon Research Institute, Eugene, Oregon, US

²⁶Department of Psychiatry, Center for Neurobiology and Behavior, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, US

²⁷Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden

²⁸Center for Psychiatry Research, Stockholm Health Care Services, Stockholm City Council, Stockholm, Sweden

²⁹Christchurch Health and Development Study, University of Otago, Christchurch, New Zealand

³⁰Division of Psychological and Social Medicine and Developmental Neurosciences, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany

³¹INSERM U894, Centre of Psychiatry and Neuroscience, Paris, France

³²Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK

- ³³Department of Medical Biology, School of Medicine, University of Split, Split, Croatia
- ³⁴The Center for Eating Disorders at Sheppard Pratt, Baltimore, Maryland, US
- ³⁵Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, RWTH Aachen University, Aachen, Germany
- ³⁶Klinikum Frankfurt/Oder, Frankfurt, Germany
- ³⁷Clinical Genetics Unit, Department of Woman and Child Health, University of Padova, Padova, Italy
- ³⁸Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland
- ³⁹Life Sciences Institute and Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan, US
- ⁴⁰Department of Emergency Psychiatry and Post-Acute Care, CHRU Montpellier, University of Montpellier, Montpellier, France
- ⁴¹Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, US
- ⁴²MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK
- ⁴³School of Social and Community Medicine, University of Bristol, Bristol, UK
- ⁴⁴Department of Psychosomatic Medicine and Psychotherapy, Hannover Medical School, Hannover, Germany
- ⁴⁵Department of Nutrition and Dietetics, Harokopio University, Athens, Greece
- ⁴⁶Department of Neurosciences, University of Padova, Padova, Italy
- ⁴⁷College of Nursing, Seattle University, Seattle, Washington, US
- ⁴⁸Department of Psychology, Virginia Commonwealth University, Richmond, Virginia, US
- ⁴⁹Department of Psychiatry, Athens University Medical School, Athens University, Athens, Greece
- ⁵⁰L'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France
- ⁵¹L'institut du thorax, CHU Nantes, Nantes, France
- ⁵²Department of Psychiatric Genetics, Poznan University of Medical Sciences, Poznan, Poland
- ⁵³Barcelona Institute of Science and Technology, Barcelona, Spain
- ⁵⁴Universitat Pompeu Fabra, Barcelona, Spain
- ⁵⁵Centro de Investigación Biomédica en Red en Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain

- ⁵⁶Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, US
- ⁵⁷Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital of Würzburg, Centre for Mental Health, Würzburg, Germany
- ⁵⁸Estonian Genome Center, University of Tartu, Tartu, Estonia
- ⁵⁹Program in Medical and Population Genetics, Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, US
- ⁶⁰Genomics and Disease, Bioinformatics and Genomics Programme, Centre for Genomic Regulation, Barcelona, Spain
- ⁶¹Department of Psychiatry, University Hospital of Bellvitge –IDIBELL and CIBERobn, Barcelona, Spain
- ⁶²Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain
- ⁶³Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University (LMU), Munich, Germany
- ⁶⁴Schön Klinik Roseneck affiliated with the Medical Faculty of the University of Munich (LMU), Munich, Germany
- ⁶⁵Department of Child and Adolescent Psychiatry, University Hospital Essen, University of Duisburg-Essen, Essen, Germany
- ⁶⁶Department of Cancer, Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic
- ⁶⁷Institute of Human Genetics, University of Bonn School of Medicine & University Hospital Bonn, Bonn, Germany
- ⁶⁸Department of Genomics, Life and Brain Center, University of Bonn, Bonn, Germany
- ⁶⁹Department of Psychiatry (UPK), University of Basel, Basel, Switzerland
- ⁷⁰Department of Biomedicine, University of Basel, Basel, Switzerland
- ⁷¹Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, Canada
- ⁷²Department of Psychiatry, Psychotherapy and Psychosomatics, Martin Luther University of Halle-Wittenberg, Halle, Germany
- ⁷³1st Psychiatric Department, National and Kapodistrian University of Athens, Medical School, Eginition Hospital, Athens, Greece
- ⁷⁴QIMR Berghofer Medical Research Institute, Brisbane, Australia

- ⁷⁵CMME (Groupe Hospitalier Sainte-Anne), Paris Descartes University, Paris, France
- ⁷⁶Department of Biomedicine, Aarhus University, Aarhus, Denmark
- ⁷⁷The Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Aarhus, Denmark
- ⁷⁸Centre for Integrative Sequencing, iSEQ, Aarhus University, Aarhus, Denmark
- ⁷⁹Bioinformatics Research Centre, Aarhus University, Aarhus, Denmark
- ⁸⁰Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, US
- ⁸¹Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, US
- ⁸²Department of Psychiatry, Weill Cornell Medical College, New York, New York, US
- ⁸³Department of Medical and Molecular Genetics, King's College London, Guy's Hospital, London, UK
- ⁸⁴Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
- ⁸⁵Zorg op Orde, Leidschendam, The Netherlands
- ⁸⁶Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia
- ⁸⁷Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany
- ⁸⁸Department of Psychiatry, and Genetics and Genomics Sciences, Division of Psychiatric Genomics, Icahn School of Medicine at Mount Sinai, New York, New York, US
- ⁸⁹Biological Psychiatry Laboratory, McLean Hospital/Harvard Medical School, Boston, Massachusetts, US
- ⁹⁰Eating Disorders Unit, Parklandklinik, Bad Wildungen, Germany
- ⁹¹Department of Molecular Life Science, Division of Basic Medical Science and Molecular Medicine, School of Medicine, Tokai University, Isehara, Japan
- ⁹²Faculty of Health Sciences, Palacky University, Olomouc, Czech Republic
- ⁹³Eating Recovery Center, Denver, Colorado, US
- ⁹⁴Department of Psychological Medicine, University of Otago, Christchurch, New Zealand
- ⁹⁵Canterbury District Health Board, Christchurch, New Zealand
- ⁹⁶Rheumatology Research Group, Vall d'Hebron Research Institute, Barcelona, Spain

⁹⁷Department of Psychiatry, First Faculty of Medicine, Charles University, Prague, Czech Republic

⁹⁸Center for Addiction and Mental Health, Department of Psychiatry, Institute of Medical Science, University of Toronto, Toronto, Canada

⁹⁹Department of Public Health, University of Helsinki, Helsinki, Finland

¹⁰⁰Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland

¹⁰¹Institute of Public Health and Clinical Nutrition, Department of Clinical Nutrition, University of Eastern Finland, Kuopio, Finland

¹⁰²Eating Disorders Unit, Department of Child and Adolescent Psychiatry, Medical University of Vienna, Vienna, Austria

¹⁰³Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands

¹⁰⁴Department of Psychiatry, University of California San Diego, San Diego, California, US

¹⁰⁵Department of Pathology and Biomedical Science, University of Otago, Christchurch, New Zealand

¹⁰⁶Health Services Research Unit, University of Aberdeen, Aberdeen, UK

¹⁰⁷Department of Psychiatry, Seoul Paik Hospital, Inje University, Seoul, Korea

¹⁰⁸Rheumatology Unit, Department of Medicine, Center for Molecular Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden

¹⁰⁹Department of Psychology, Michigan State University, East Lansing, Michigan, US

¹¹⁰Department of Mental Disorders, Norwegian Institute of Public Health, Oslo, Norway

¹¹¹National Centre for Register-Based Research, Aarhus BSS, Aarhus University, Aarhus, Denmark

¹¹²Centre for Integrated Register-based Research (CIRRAU), Aarhus University, Aarhus, Denmark

¹¹³Department of Clinical Science, K.G. Jebsen Centre for Psychosis Research, Norwegian Centre for Mental Disorders Research (NORMENT), University of Bergen, Bergen, Norway

¹¹⁴Dr. Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway

¹¹⁵Department of Clinical Medicine, Laboratory Building, Haukeland University Hospital, Bergen, Norway

¹¹⁶Institute of Medical Science, University of Toronto, Toronto, Canada

- ¹¹⁷American School of Professional Psychology, Argosy University, Northern Virginia, Arlington, Virginia, US
- ¹¹⁸Department of Cancer Epidemiology and Prevention, M Skłodowska-Curie Cancer Center - Oncology Center, Warsaw, Poland
- ¹¹⁹BESE Division, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia
- ¹²⁰Department of Psychiatry, University of Lausanne-University Hospital of Lausanne (UNIL-CHUV), Lausanne, Switzerland
- ¹²¹Department of Psychiatry, University of Campania "Luigi Vanvitelli", Naples, Italy
- ¹²²Center for Integrative Genomics, University of Lausanne, Lausanne, Switzerland
- ¹²³Department of Paediatric Laboratory Medicine, The Hospital for Sick Children, Toronto, Canada
- ¹²⁴Department of Psychiatry, Psychosomatics and Psychotherapy, University of Würzburg, Würzburg, Germany
- ¹²⁵Department of Psychiatry, University College Cork, Cork, Ireland
- ¹²⁶Eist Linn Adolescent Unit, Bessborough, Health Service Executive South, Cork, Ireland
- ¹²⁷Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia
- ¹²⁸Molecular Epidemiology Section (Department of Medical Statistics), Leiden University Medical Centre, Leiden, The Netherlands
- ¹²⁹Department of Psychiatry, Faculty of Medicine, University of Geneva, Geneva, Switzerland
- ¹³⁰Division of Child and Adolescent Psychiatry, Geneva University Hospital, Geneva, Switzerland
- ¹³¹Department of Psychiatry and Behavioral Science, University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota, US
- ¹³²National Center for PTSD, VA Boston Healthcare System, Department of Psychiatry, Boston University School of Medicine, Boston, Massachusetts, US
- ¹³³Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Salerno, Italy
- ¹³⁴Queensland Brain Institute, University of Queensland, Brisbane, Australia
- ¹³⁵Department of Neuroscience, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Florence, Italy
- ¹³⁶Center for Neurobehavioral Genetics, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, US
- ¹³⁷Kartini Clinic, Portland, Oregon, US

- ¹³⁸Center for Human Genome Research at the Massachusetts General Hospital, Boston, Massachusetts, US
- ¹³⁹Biostatistics and Computational Biology Unit, University of Otago, Christchurch, New Zealand
- ¹⁴⁰Saint Joan de Déu Research Institute, Saint Joan de Déu Barcelona Children's Hospital, Barcelona, Spain
- ¹⁴¹Institute of Biomedicine (IBUB), University of Barcelona, Barcelona, Spain
- ¹⁴²Department of Genetics, Microbiology and Statistics, University of Barcelona, Barcelona, Spain
- ¹⁴³Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- ¹⁴⁴Department of Health Science, University of Florence, Florence, Italy
- ¹⁴⁵Department of Biometry, University of Helsinki, Helsinki, Finland
- ¹⁴⁶Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, Massachusetts, US
- ¹⁴⁷Stanley Center for Psychiatric Research, Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, US
- ¹⁴⁸Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin, Berlin, Germany
- ¹⁴⁹Eating Disorders Research and Treatment Center, Department of Child and Adolescent Psychiatry, Faculty of Medicine, Technische Universität Dresden, Dresden, Germany
- ¹⁵⁰Department of Psychiatry, Neurobiology, Pharmacology, and Biotechnologies, University of Pisa, Pisa, Italy
- ¹⁵¹Department of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
- ¹⁵²Department of Neurosciences, Padua Neuroscience Center, University of Padova, Padova, Italy
- ¹⁵³Institute of Medical Statistics, Computer and Data Sciences, Jena University Hospital, Jena, Germany
- ¹⁵⁴Department of Genetics and Genomic Biology, The Hospital for Sick Children, Toronto, Canada
- ¹⁵⁵J. Craig Venter Institute (JCVI), La Jolla, California, US
- ¹⁵⁶Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria
- ¹⁵⁷Department of Pediatrics and Center of Applied Genomics, First Faculty of Medicine, Charles University, Prague, Czech Republic

- ¹⁵⁸Center for Eating Disorders Ursula, Rivierduinen, Leiden, The Netherlands
- ¹⁵⁹Department of Psychiatry, Leiden University Medical Centre, Leiden, The Netherlands
- ¹⁶⁰Department of Child and Adolescent Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
- ¹⁶¹IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy
- ¹⁶²Department of Psychiatry and Biobehavioral Science, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, US
- ¹⁶³David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, US
- ¹⁶⁴Department of Cell Biology and Physiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, US
- ¹⁶⁵Department of Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland
- ¹⁶⁶Department of Psychiatry, University of Naples SUN, Naples, Italy
- ¹⁶⁷Department of Psychiatry, University of Perugia, Perugia, Italy
- ¹⁶⁸Brain Sciences Department, Stremble Ventures, Limassol, Cyprus
- ¹⁶⁹Adolescent Health Unit, Second Department of Pediatrics, "P. & A. Kyriakou" Children's Hospital, University of Athens, Athens, Greece
- ¹⁷⁰Pediatric Intensive Care Unit, "P. & A. Kyriakou" Children's Hospital, University of Athens, Athens, Greece
- ¹⁷¹Faculty of Social and Behavioral Sciences, Utrecht University, Utrecht, The Netherlands
- ¹⁷²School of Psychology, Flinders University, Adelaide, Australia
- ¹⁷³Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- ¹⁷⁴Department of Psychiatry, Faculty of Medicine, University of Toronto, Toronto, Canada
- ¹⁷⁵Toronto General Hospital, Toronto, Canada
- ¹⁷⁶Institute of Translational Genomics, Helmholtz Zentrum München, Neuherberg, Germany
- ¹⁷⁷Department of Internal Medicine VI, Psychosomatic Medicine and Psychotherapy, University Medical Hospital Tuebingen, Tuebingen, Germany
- ¹⁷⁸Broad Institute of MIT and Harvard, Cambridge, USA
- ¹⁷⁹Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland

- ¹⁸⁰Karolinska Institutet, Stockholm, Sweden
- ¹⁸¹Leiden University Medical Centre, Leiden, The Netherlands
- ¹⁸²VU University, Amsterdam, The Netherlands
- ¹⁸³Oslo University Hospital and University of Oslo, Oslo, Norway
- ¹⁸⁴Harvard Medical School, Cambridge, USA
- ¹⁸⁵Department of Twin Research and Genetic Epidemiology, King's College London, London, UK
- ¹⁸⁶Danish Headache Center, Copenhagen University Hospital, Copenhagen, Denmark
- ¹⁸⁷University of Barcelona, Barcelona, Spain
- ¹⁸⁸Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol, UK
- ¹⁸⁹Institute for Stroke and Dementia Research, Munich, Germany
- ¹⁹⁰Erasmus University Medical Centre, Rotterdam, The Netherlands
- ¹⁹¹Danish Headache Center, Department of Neurology, Rigshospitalet, Denmark
- ¹⁹²University of Tuebingen, Tuebingen, Germany
- ¹⁹³23&Me Inc., Mountain View, USA
- ¹⁹⁴Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Australia
- ¹⁹⁵Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland
- ¹⁹⁶Folkhälsan Institute of Genetics, Helsinki, Finland
- ¹⁹⁷Decode genetics Inc., Reykjavik, Iceland
- ¹⁹⁸University of Oulu, Biocenter Oulu, Finland
- ¹⁹⁹University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- ²⁰⁰Harvard Medical School, Boston, USA
- ²⁰¹National Institute on Aging, Bethesda, USA
- ²⁰²School of Medicine, University of Tampere, Tampere, Finland
- ²⁰³Vall d'Hebron Research Institute, Barcelona, Spain
- ²⁰⁴Department of Twin Research and Genetic Epidemiology, King's College London, UK
- ²⁰⁵Medical Research Council (MRC) Integrative Epidemiology Unit, University of Bristol, Bristol
- ²⁰⁶Max Planck Institute of Psychiatry, Munich, Germany

- ²⁰⁷Danish Headache Center, Dept. of Neurology, Department of Neurology, Rigshospitalet, Denmark
- ²⁰⁸Headache Research Group, Universitat Autònoma de Barcelona, Barcelona, Barcelona
- ²⁰⁹Sutter Health, Sacramento, USA
- ²¹⁰Department of Medicine, University of Turku, Turku, Finland
- ²¹¹Population Health Research Institute, St George's University of London, London, UK
- ¹Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-17177 Stockholm, Sweden
- ²Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-17177 Stockholm, Sweden
- ³UCL Institute of Neurology, Queen Square, London, UK
- ⁴Division of Brain Sciences, Department of Medicine, Imperial College, London, UK
- ⁵UK Dementia Research Institute at Imperial College London
- ⁶Danish Headache Center, Dept. of Neurology, Copenhagen University Hospital, Glostrup, Denmark
- ⁷Institute of Biological Psychiatry, Copenhagen University Hospital MHC Sct. Hans, Roskilde, Denmark
- ⁸Novo Nordic Foundations Center for Protein Research, Copenhagen University, Denmark
- ⁹Department of Psychiatry, University of North Carolina at Chapel Hill, North Carolina, US
- ¹⁰School of Psychology, Curtin University, Perth, Australia
- ¹¹Division of Paediatrics, School of Medicine, The University of Western Australia, Perth, Australia
- ¹²23andMe, Inc., Mountain View, CA, 94041, USA
- ¹³Department of Psychiatry, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, Iowa
- ¹⁴Institute of Psychiatry, MRC Social, Genetic and Developmental Psychiatry Centre, King's College London, UK
- ¹⁵National Institute for Health Research Biomedical Research Centre, South London and Maudsley National Health Service Trust, London, UK
- ¹⁶Department of Nutrition, University of North Carolina, Chapel Hill, NC, 27599-7264, USA

¹⁷Departments of Genetics, University of North Carolina, Chapel Hill, NC, 27599-7264, USA

Acknowledgments

J. Bryois was funded by a grant from the Swiss National Science Foundation (P400PB_180792). N.G.S. was supported by the Wellcome Trust (108726/Z/15/Z). N. Skene and L. Brueggeman performed part of the work at the Systems Genetics of Neurodegeneration summer school funded by BMBF as part of the e:Med program (FKZ 01ZX1704). J. Hjerling-Leffler was funded by the Swedish Research Council (Vetenskapsrådet, award 2014-3863), StratNeuro, the Wellcome Trust (108726/Z/15/Z) and the Swedish Brain Foundation (Hjärnfonden). PFS was supported by the Swedish Research Council (Vetenskapsrådet, award D0886501), the Horizon 2020 Program of the European Union (COSYN, RIA grant agreement n° 610307), and US NIMH (U01 MH109528 and R01 MH077139). K. Heilbron was supported by The Michael J. Fox Foundation for Parkinson's Research (grant MJFF12737). E. Arenas was supported by the Swedish Research Council (VR 2016-01526), Swedish Foundation for Strategic Research (SLA SB16-0065), Karolinska Institutet (SFO Strat. Regen., Senior grant 2018), Cancerfonden (CAN 2016/572), Hjärnfonden (FO2017-0059) and Chen Zuckeberg Initiative: Neurodegeneration Challenge Network (2018-191929-5022). C. Bulik acknowledges funding from the Swedish Research Council (Vetenskapsrådet, award: 538-2013-8864) and the Klarman Family Foundation. This work is supported by the UK Dementia Research Institute which receives its funding from UK DRI Ltd, funded by the UK Medical Research Council, Alzheimer's Society and Alzheimer's Research UK. We thank the research participants from 23andMe and other cohorts for their contribution to this study.

Data availability

All single-cell expression data are publicly available. Most summary statistics used in this study are publicly available. The migraine GWAS can be obtained by contacting the authors⁶¹. The full Parkinson's disease summary statistics from 23andMe can be obtained under an agreement that protects the privacy of 23andMe research participants (<https://research.23andme.com/collaborate/#publication>). The 10,000 most associated SNPs from the 23andMe cohort are available in Supplementary Table 12.

Code availability

The code used to generate these results is available at: https://github.com/jbryois/scRNA_disease. An R package for performing cell type enrichments using magma is also available from: https://github.com/NathanSkene/MAGMA_Celltyping.

References

1. Pardiñas AF, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. *Nat Genet.* 2018; 50:381–389. [PubMed: 29483656]
2. Lee JJ, Wedow R, Okbay. Gene discovery and polygenic prediction from a genome-wide association study of educational attainment in 1.1 million individuals. *Nat Genet.* 2018; 50:1112–1121. [PubMed: 30038396]
3. Nagel M, et al. Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways. *Nat Genet.* 2018; 50:920–927. [PubMed: 29942085]
4. Yengo L, et al. Meta-analysis of genome-wide association studies for height and body mass index in ~700000 individuals of European ancestry. *Hum Mol Genet.* 2018; 27:3641–3649. [PubMed: 30124842]
5. Maurano MT, et al. Systematic localization of common disease-associated variation in regulatory DNA. *Science* (80-). 2012; 337:1190–1195.
6. Akbarian S, et al. The PsychENCODE project. *Nature Neuroscience.* 2015; 18:1707–1712. [PubMed: 26605881]

7. Aguet F, et al. Genetic effects on gene expression across human tissues. *Nature*. 2017; 550:204–213. [PubMed: 29022597]
8. Roadmap Epigenomics Consortium. et al. Integrative analysis of 111 reference human epigenomes. *Nature*. 2015; 518:317–329. [PubMed: 25693563]
9. Ongen H, et al. Estimating the causal tissues for complex traits and diseases. *Nat Genet*. 2017; 49:1676–1683. [PubMed: 29058715]
10. Skene NG, Grant SGN. Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and expression weighted cell type enrichment. *Front Neurosci*. 2016; 10:1–11. [PubMed: 26858586]
11. Skene NG, et al. Genetic identification of brain cell types underlying schizophrenia. *Nat Genet*. 2018; 50:825–833. [PubMed: 29785013]
12. Finucane HK, et al. Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. *Nat Genet*. 2018; 50:621–629. [PubMed: 29632380]
13. Calderon D, et al. Inferring relevant cell types for complex traits by using single-cell gene expression. *Am J Hum Genet*. 2017; 101:686–699. [PubMed: 29106824]
14. Savage JE, et al. Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. *Nat Genet*. 2018; 50:912–919. [PubMed: 29942086]
15. Coleman JRI, et al. Biological annotation of genetic loci associated with intelligence in a meta-analysis of 87,740 individuals. *Mol Psychiatry*. 2019; 24:182–197. [PubMed: 29520040]
16. Jansen IE, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nat Genet*. 2019; 51:404–413. [PubMed: 30617256]
17. Nalls MA, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol*. 2019; 18:1091–1102. [PubMed: 31701892]
18. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLoS Comput Biol*. 2015; 11
19. Finucane HK, et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat Genet*. 2015; 47:1228–1235. [PubMed: 26414678]
20. Jevtic S, Sengar AS, Salter MW, McLaurin JA. The role of the immune system in Alzheimer disease: Etiology and treatment. *Ageing Research Reviews*. 2017; 40:84–94. [PubMed: 28941639]
21. Jansen IE, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. *Nature Genetics*. 2019; 51:404–413. [PubMed: 30617256]
22. Kunkle BW, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat Genet*. 2019; 51:414–430. [PubMed: 30820047]
23. O'Leary DH, et al. Carotid-Artery Intima and Media Thickness as a Risk Factor for Myocardial Infarction and Stroke in Older Adults. *N Engl J Med*. 1999; 340:14–22. [PubMed: 9878640]
24. Zeisel A, et al. Molecular architecture of the mouse nervous system. *Cell*. 2018; 174:999–1014.e22. [PubMed: 30096314]
25. Anttila V, et al. Analysis of shared heritability in common disorders of the brain. *Science* (80-). 2018; 360
26. Keren-Shaul H, et al. A unique microglia type associated with restricting development of alzheimer's disease. *Cell*. 2017; 169
27. Braak H, et al. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging*. 2003; 24:197–211. [PubMed: 12498954]
28. Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson's disease. *Movement Disorders*. 2013; 28:41–50. [PubMed: 22791686]
29. Poewe W, et al. Parkinson disease. *Nat Rev Dis Prim*. 2017; 3:17013. [PubMed: 28332488]
30. Halliday GM, et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. *Ann Neurol*. 1990; 27:373–385. [PubMed: 1972319]
31. Delaville C, de Deurwaerdère P, Benazzouz A. Noradrenaline and Parkinson's disease. *Frontiers in Systems Neuroscience*. 2011; doi: 10.3389/fnsys.2011.00031

32. Rinne JO, Ma SY, Lee MS, Collan Y, R oytt  M. Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients. *Park Relat Disord.* 2008; 14:553–557.
33. Braak H, R ub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. *J Neural Transm.* 2003; 110:517–536. [PubMed: 12721813]
34. Liddle RA. Parkinson's disease from the gut. *Brain Research.* 2018; 1693:201–206. [PubMed: 29360467]
35. Saunders A, et al. Molecular diversity and specializations among the cells of the adult mouse brain. *Cell.* 2018; 174:1015–1030.e16. [PubMed: 30096299]
36. Habib N, et al. Massively parallel single-nucleus RNA-seq with DroNc-seq. *Nat Methods.* 2017; 14:955. [PubMed: 28846088]
37. Lake BB, et al. Integrative single-cell analysis of transcriptional and epigenetic states in the human adult brain. *Nat Biotechnol.* 2018; 36:70–80. [PubMed: 29227469]
38. Lesnick TG, et al. A genomic pathway approach to a complex disease: Axon guidance and Parkinson disease. *PLoS Genet.* 2007; 3:0984–0995.
39. Moran LB, et al. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. *Neurogenetics.* 2006; 7:1–11. [PubMed: 16344956]
40. Kannarkat GT, Boss JM, Tansey MG. The role of innate and adaptive immunity in parkinson's disease. *Journal of Parkinson's Disease.* 2013; 3:493–514.
41. Gagliano SA, et al. Genomics implicates adaptive and innate immunity in Alzheimer's and Parkinson's diseases. *Ann Clin Transl Neurol.* 2016; 3:924–933. [PubMed: 28097204]
42. Dijkstra AA, et al. Evidence for immune response, axonal dysfunction and reduced endocytosis in the substantia nigra in early stage Parkinson's disease. *PLoS One.* 2015; 10
43. Lake BB, et al. Neuronal subtypes and diversity revealed by single-nucleus RNA sequencing of the human brain. *Science (80-).* 2016; 352:1586–1590.
44. Sathyamurthy A, et al. Massively Parallel Single Nucleus Transcriptional Profiling Defines Spinal Cord Neurons and Their Activity during Behavior. *Cell Rep.* 2018; 22:2216–2225. [PubMed: 29466745]
45. Lake BB, et al. A comparative strategy for single-nucleus and single-cell transcriptomes confirms accuracy in predicted cell-type expression from nuclear RNA. *Sci Rep.* 2017; 7
46. Caspi A, et al. The p factor: One general psychopathology factor in the structure of psychiatric disorders? *Clin Psychol Sci.* 2014; 2:119–137. [PubMed: 25360393]
47. Sullivan PF, Geschwind DH. Defining the Genetic, Genomic, Cellular, and Diagnostic Architectures of Psychiatric Disorders. *Cell.* 2019; 177:162–183. [PubMed: 30901538]
48. Reynolds RH, et al. Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson's disease heritability. *npj Park Dis.* 2019; 5:6.
49. Singaram C, et al. Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. *Lancet.* 1995; 346:861–864. [PubMed: 7564669]
50. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Lewy Bodies in the Enteric Nervous System in Parkinson's Disease. *Arch Histol Cytol.* 1989; 52:191–194.
51. Stokholm MG, Danielsen EH, Hamilton-Dutoit SJ, Borghammer P. Pathological α -synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. *Ann Neurol.* 2016; 79:940–949. [PubMed: 27015771]
52. Svensson E, et al. Vagotomy and subsequent risk of Parkinson's disease. *Ann Neurol.* 2015; 78:522–529. [PubMed: 26031848]
53. Gilman S, et al. Second consensus statement on the diagnosis of multiple system atrophy. *Neurology.* 2008; 71:670–676. [PubMed: 18725592]
54. Nalls MA, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. *Nat Genet.* 2014; 46:989–993. [PubMed: 25064009]
55. Wakabayashi K, Hayashi S, Yoshimoto M, Kudo H, Takahashi H. NACP/ α -synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. *Acta Neuropathol.* 2000; 99:14–20. [PubMed: 10651022]

56. Seidel K, et al. The brainstem pathologies of Parkinson's disease and dementia with lewy bodies. *Brain Pathol.* 2015; 25:121–135. [PubMed: 24995389]
57. Stahl EA, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. *Nat Genet.* 2019; 51:793–803. [PubMed: 31043756]
58. Wray N, Sullivan PF, PGC, M. D. D. W. G. of the. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet.* 2018; 50:668–681. [PubMed: 29700475]
59. Perry JRB, et al. Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature.* 2014; 514:92–97. [PubMed: 25231870]
60. Grove J, et al. Identification of common genetic risk variants for autism spectrum disorder. *Nat Genet.* 2019; 51:431–444. [PubMed: 30804558]
61. Gormley P, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. *Nat Genet.* 2016; 48:1296.
62. Van Rheenen W, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. *Nat Genet.* 2016; 48:1043–1048. [PubMed: 27455348]
63. Demontis D, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. *Nat Genet.* 2019; 51:63–75. [PubMed: 30478444]
64. Day FR, et al. Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nat Genet.* 2015; 47:1294–1303. [PubMed: 26414677]
65. Nelson CP, et al. Association analyses based on false discovery rate implicate new loci for coronary artery disease. *Nat Genet.* 2017; 49:1385–1391. [PubMed: 28714975]
66. Wheeler E, et al. Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations. *PLoS Med.* 2017; 14:1–30.
67. Hibar DP, et al. Novel genetic loci associated with hippocampal volume. *Nat Commun.* 2017; 8:13624. [PubMed: 28098162]
68. de Lange KM, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. *Nat Genet.* 2017; 49:256–261. [PubMed: 28067908]
69. Adams HHH, et al. Novel genetic loci underlying human intracranial volume identified through genome-wide association. *Nat Neurosci.* 2016; 19:1569–1582. [PubMed: 27694991]
70. Malik R, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet.* 2018; 50:524–537. [PubMed: 29531354]
71. Scott RA, et al. An expanded genome-wide association study of type 2 diabetes in europeans. *Diabetes.* 2017; 66:2888–2902. [PubMed: 28566273]
72. Shungin D, et al. New genetic loci link adipose and insulin biology to body fat distribution. *Nature.* 2015; 518:187–196. [PubMed: 25673412]
73. Watson HJ, et al. Genome-wide association study identifies eight risk loci and implicates metabolic-psychiatric origins for anorexia nervosa. *Nat Genet.* 2019; 51:1207–1214. [PubMed: 31308545]
74. Willer CJ, Li Y, Abecasis GR. METAL: Fast and efficient meta-analysis of genomewide association scans. *Bioinformatics.* 2010; 26:2190–2191. [PubMed: 20616382]
75. Bulik-Sullivan B, et al. An atlas of genetic correlations across human diseases and traits. *Nat Genet.* 2015; 47:1236–1241. [PubMed: 26414676]
76. Saunders A, et al. Molecular diversity and specializations among the cells of the adult mouse brain. *Cell.* 2018; 174:1015–1030.e16. [PubMed: 30096299]
77. Auton A, et al. A global reference for human genetic variation. *Nature.* 2015; 526:68–74. [PubMed: 26432245]
78. Watanabe K, Umi evi Mirkov M, de Leeuw CA, van den Heuvel MP, Posthuma D. Genetic mapping of cell type specificity for complex traits. *Nat Commun.* 2019; 10
79. Finucane HK, et al. Partitioning heritability by functional annotation using genome-wide association summary statistics. *Nat Genet.* 2015; 47:1228–1235. [PubMed: 26414678]
80. Cajigas JJ, et al. The Local Transcriptome in the Synaptic Neuropil Revealed by Deep Sequencing and High-Resolution Imaging. *Neuron.* 2012; 74:453–466. [PubMed: 22578497]

81. Alexa A, Rahnenfuhrer J. topGO: Enrichment analysis for gene ontology. 2016
82. Gautier L, Cope L, Bolstad BM, Irizarry RA. Affy - Analysis of Affymetrix GeneChip data at the probe level. *Bioinformatics*. 2004; 20:307–315. [PubMed: 14960456]
83. Durinck S, Spellman PT, Birney E, Huber W. Mapping identifiers for the integration of genomic datasets with the R/Bioconductor package biomaRt. *Nat Protoc*. 2009; 4:1184–1191. [PubMed: 19617889]
84. Ritchie ME, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res*. 2015; 43:e47. [PubMed: 25605792]





Figure 1. Study design and tissue-level associations.

Heat map of trait – tissue/cell types associations ($-\log_{10}P$) for the selected traits. (a) Trait – tissue/cell types associations were performed using MAGMA and LDSC (testing for enrichment in genetic association of the top 10% most specific genes in each tissue/cell type). (b) Tissue – trait associations for selected brain related traits. (c) Tissue – trait associations for selected non-brain related traits. (d) The mean strength of association ($-\log_{10}P$) of MAGMA and LDSC is shown and the bar color indicates whether the tissue is significantly associated with both methods, one method or none (significance threshold: 5% false discovery rate).

a



b





Figure 2. Association of selected brain related traits with cell types from the entire nervous system.

Associations of the top 10 most associated cell types are shown. **(a)** Conditional analysis results for Parkinson's disease using MAGMA. The label indicates the cell type the association analysis is being conditioned on. **(b)** The mean strength of association ($-\log_{10}P$) of MAGMA and LDSC is shown and the bar color indicates whether the cell type is significantly associated with both methods, one method or none (significance threshold: 5% false discovery rate).

a



b




Figure 3. Replication of cell type – trait associations in mouse datasets.

Tissue – trait associations are shown for the 10 most association cell types among 88 cell types from 9 different brain regions. **(a)** Tissue – trait associations are shown for the 10 most association cell types among 24 cell types from 5 different brain regions. **(b)** The mean strength of association ($-\log_{10}P$) of MAGMA and LDSC is shown and the bar color indicates whether the cell type is significantly associated with both methods, one method or none (significance threshold: 5 % false discovery rate).




Figure 4. Human replication of cell type – trait associations.

Cell type - trait associations for 15 cell types (derived from single-nuclei RNA-seq) from 2 different brain regions (cortex, hippocampus). **(a)** Cell type - trait associations for 31 cell types (derived from single-nuclei RNA-seq) from 3 different brain regions (frontal cortex, visual cortex and cerebellum). **(b)** The mean strength of association ($-\log_{10}P$) of MAGMA and LDSC is shown and the bar color indicates whether the cell type is significantly associated with both methods, one method or none (significance threshold: 5% false discovery rate). INT (intelligence), SCZ (schizophrenia), EDU (educational attainment), NEU (neuroticism), BMI (body mass index), BIP (bipolar disorder), MDD (Major depressive disorder), MEN (age at menarche), ASD (autism spectrum disorder), MIG (migraine), PAR (Parkinson's disease), ADHD (attention deficit hyperactivity disorder), ICV (intracranial volume), HIP (hippocampal volume), AN (anorexia nervosa), ALZ (Alzheimer's disease), ALS (amyotrophic lateral sclerosis), STR (stroke).




Figure 5. Enrichment of Parkinson’s disease differentially expressed genes in cell types from the substantia nigra.

Enrichment of the 500 most up/down regulated genes (Braak stage 0 vs Braak stage 1–2, 3–4 and 5–6, as well as cases vs controls) in postmortem human substantia nigra gene expression samples. The enrichments were obtained using EWCE¹⁰. A star shows significant enrichments after multiple testing correction ($P < 0.05 / (25 * 6)$).